var title_f19_11_19632="Black widow spider 2";
var content_f19_11_19632=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F57539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F57539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Widow spider C",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Julian White, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19632=[""].join("\n");
var outline_f19_11_19632=null;
var title_f19_11_19633="Pelvic lymphadenectomy7";
var content_f19_11_19633=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Full exposure of obturator nerve lateral to iliac vessels",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ken Hatch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19633=[""].join("\n");
var outline_f19_11_19633=null;
var title_f19_11_19634="Lichen simplex chronicus";
var content_f19_11_19634=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen simplex chronicus of the vulva (skin lichenification from chronic scratching)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Lichenification and swelling in localized plaque of lichen simplex chronicus.",
"    <br/>",
"    (B) Marked lichenification, erosions, and crusting in lichen simplex chronicus of left labium major.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fisher BK, Margesson LJ. Genital Skin Disorders: Diagnosis and Treatment. Mosby, St. Louis, Missouri 1998. p.158. Copyright &copy; 1998 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19634=[""].join("\n");
var outline_f19_11_19634=null;
var title_f19_11_19635="Leak after Roux-en-Y gastric bypass";
var content_f19_11_19635=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57699&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Leak after Roux-en-Y gastric bypass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small amount of extravasation at gastrojejunal anastomosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19635=[""].join("\n");
var outline_f19_11_19635=null;
var title_f19_11_19636="Endosc long segment Barrett";
var content_f19_11_19636=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Follow-up endoscopy with biopsies after eradication of long-segment Barrett's esophagus with radiofrequency ablation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     (A)",
"    </strong>",
"    High-resolution white light image of the distal esophagus showing complete regeneration with neosquamous epithelium after successful treatment with radiofrequency ablation.",
"    <br>",
"     <strong>",
"      (B)",
"     </strong>",
"     Corresponding narrow band imaging view.",
"     <br>",
"      <strong>",
"       (C)",
"      </strong>",
"      Four quadrant biopsies are obtained for every 1 to 2 cm over the entire length of the initial Barrett's segment.",
"      <br>",
"       <strong>",
"        (D)",
"       </strong>",
"       Normal appearing neosquamocolumnar junction.",
"       <br>",
"        <strong>",
"         (E)",
"        </strong>",
"        Corresponding narrow band imaging view.",
"        <br>",
"         <strong>",
"          (F)",
"         </strong>",
"         To histologically confirm the absence of intestinal metaplasia, four quadrant biopsies are obtained 5 mm distal to the neosquamocolumnar junction.",
"         <div class=\"footnotes\">",
"         </div>",
"         <div class=\"reference\">",
"          Reproduced with permission of www.endosurgery.eu. Copyright &copy; 2010 Esophageal Research Foundation Amsterdam.",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19636=[""].join("\n");
var outline_f19_11_19636=null;
var title_f19_11_19637="Pelvimetry 1";
var content_f19_11_19637=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Vaginal examination to determine the diagonal conjugate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     P: sacral promontory; S: symphysis pubis.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy;1980 McGraw Hill. p.280.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19637=[""].join("\n");
var outline_f19_11_19637=null;
var title_f19_11_19638="Sciatic nerve anatomy";
var content_f19_11_19638=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    Sciatic nerve anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 705px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19638=[""].join("\n");
var outline_f19_11_19638=null;
var title_f19_11_19639="Bipolar disorder in adults: Epidemiology and diagnosis";
var content_f19_11_19639=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bipolar disorder in adults: Epidemiology and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/11/19639/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/11/19639/contributors\">",
"     Jeffrey Stovall, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/11/19639/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/11/19639/contributors\">",
"     Paul Keck, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/11/19639/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/11/19639/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/11/19639/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is an illness characterized by periods of mood elevation. Patients with bipolar I disorder have episodes of sustained mania, and often experience depressive episodes. Patients with bipolar II disorder have one or more major depressive episodes, with at least one hypomanic episode.",
"   </p>",
"   <p>",
"    Recognition of bipolar disorder is important for at least two reasons: it is associated with substantial morbidity and mortality if untreated, and treatment differs from that of unipolar depression. Bipolar disorder is often misdiagnosed, especially when patients present with symptoms of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/1\">",
"     1",
"    </a>",
"    ]. A careful history, including information from family members, may find evidence of prior manic, mixed, or hypomanic episodes.",
"   </p>",
"   <p>",
"    This discussion will address the epidemiology, clinical manifestations, and diagnosis of bipolar disorder. Issues related to acute treatment and maintenance therapy for bipolar disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=see_link\">",
"     \"Bipolar disorder in adults: Maintenance treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nationally representative sample of the United States adult population found the lifetime prevalence of bipolar I disorder is approximately 1.0 percent and the prevalence of bipolar II is 1.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/2\">",
"     2",
"    </a>",
"    ]. A spectrum of bipolar conditions has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/3\">",
"     3",
"    </a>",
"    ], including subthreshold bipolar disorder, which have a higher prevalence (2.6 to 6.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ]. The World Health Organization identified bipolar disorder as the sixth leading cause of disability-adjusted life years worldwide among people ages 15 to 44 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The true prevalence of bipolar disorder is uncertain; the diagnosis is likely to be missed when patients are seen with depression and not specifically asked about symptoms suggesting prior episodes of mania or hypomania [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. In a study of outpatients being treated for depression in a family medicine clinic, a screening questionnaire for bipolar disorder (the Mood Disorder Questionnaire or MDQ [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/9\">",
"     9",
"    </a>",
"    ]) was positive in 21.3 percent; two thirds of those screening positive had never been diagnosed with bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/8\">",
"     8",
"    </a>",
"    ]. The sensitivity and specificity of the MDQ in this population was 0.6 and 0.9 respectively, when results of screening were compared to DSM-IV criteria as determined by the Structured Clinical Interview.",
"   </p>",
"   <p>",
"    Bipolar I disorder affects men and women equally; bipolar II disorder is more common in women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/3\">",
"     3",
"    </a>",
"    ]. The age of onset is generally between 15 and 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Newly diagnosed mania is uncommon in children and in adults over the age of 65 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Family, twin, and adoption studies demonstrate the importance of genetics in the pathogenesis of bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. The approximate lifetime risk in relatives of a bipolar proband is 40 to 70 percent for a monozygotic twin and 5 to 10 percent for a first degree relative, compared with 0.5 to 1.5 percent for an unrelated person [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/16\">",
"     16",
"    </a>",
"    ]. In a large population study of 2 million nuclear families in Sweden, risk for bipolar disorder was increased if a parent (RR 6.4, 95% CI 5.9-7.1) or sibling (RR 7.9, 7.1-8.8) had bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/18\">",
"     18",
"    </a>",
"    ]. Risk for bipolar disorder was also increased, though to a lesser extent (RR 2.4-3.9), in first degree relatives of patients with schizophrenia, and risk of schizophrenia was similarly increased in relatives of patients with bipolar disorder, indicating some common genetic effect.",
"   </p>",
"   <p>",
"    The search for candidate genes has been the subject of considerable study, although no single gene has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. It is likely that a complex interaction between genetic and environmental factors is involved. Most candidate gene studies have focused upon neurotransmitter systems influenced by the medications used in the clinical management of this disorder, but no clear findings have emerged [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Linkage studies have suggested a role for the tryptophan hydroxylase 2 (TPH2) gene [",
"      <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/19\">",
"       19",
"      </a>",
"      ]; tryptophan hydroxylase is the rate limiting enzyme in the synthetic pathway for serotonin.",
"     </li>",
"     <li>",
"      Genome wide association studies have found a variety of genetic variants associated with bipolar disorder, with CACNA1C the most consistent susceptibility locus. This gene codes for a subunit of a calcium channel and is involved in channel gating [",
"      <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/20\">",
"       20",
"      </a>",
"      ]. A role for calcium channel function in bipolar disease is suggested by a study in which",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , one of the most common therapeutic agents for bipolar disease, resulted in downregulation of calcium channel subunits in mouse brain tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of a specific mood disorder is based on a patient's presenting symptoms and history of prior symptoms. Diagnostic criteria for bipolar disorder are discussed below (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Bipolar disorder'",
"    </a>",
"    below). The distinction between bipolar disorder, depression, and other depressive syndromes is presented in a flow diagram (",
"    <a class=\"graphic graphic_algorithm graphicRef74999 \" href=\"UTD.htm?20/3/20543\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mania",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic criteria for mania from the American Psychiatric Association are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef81976 \" href=\"UTD.htm?3/53/3932\">",
"     table 1",
"    </a>",
"    ) and include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A distinct period of abnormally and persistently elevated, expansive, or irritable mood, lasting at least one week (or any duration if hospitalization is necessary)",
"     </li>",
"     <li>",
"      During the period of mood disturbance, at least three or more of the following symptoms are present:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      inflated self esteem or grandiosity",
"     </li>",
"     <li>",
"      decreased need for sleep",
"     </li>",
"     <li>",
"      more talkative than usual",
"     </li>",
"     <li>",
"      racing thoughts or flight of ideas",
"     </li>",
"     <li>",
"      distractibility",
"     </li>",
"     <li>",
"      increase in goal-directed activity",
"     </li>",
"     <li>",
"      excessive involvement in pleasurable activities that have a high potential for painful consequences, such as spending money or sexual indiscretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mood disturbance leads to significant impairment in social or occupational functioning.",
"     </li>",
"     <li>",
"      The symptoms are not directly due to substance use or a general medical illness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common behavioral symptoms associated with manic episodes include pressured speech, hyperverbosity, physical hyperactivity and agitation, decreased need for sleep, hypersexuality, and extravagance (ie, financial, social, and recreational) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/23\">",
"     23",
"    </a>",
"    ]. Less common features include violence, religiosity, pronounced regression, and catatonia. Impaired insight is a frequent component of the manic state and may impair compliance with medications.",
"   </p>",
"   <p>",
"    Patients with mania may experience depression, irritability, expansiveness, or mood lability during an episode of mania as often as they experience euphoria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/23\">",
"     23",
"    </a>",
"    ]. A \"mixed episode\" is characterized by a sufficient number of depressive symptoms to meet the criteria for a major depressive episode while also meeting the criteria for mania.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Hypomania",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypomania refers to a briefer duration of manic symptoms (at least four days), and is often used to refer to a less severe level of symptoms. The DSM-IV-TR criteria are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef70757 \" href=\"UTD.htm?22/39/23164\">",
"     table 2",
"    </a>",
"    ). Psychosis does not occur with hypomania, but often does with mania. Hypomania causes mild functional impairment, and can even improve functioning, while mania causes distortions of perception and somatic functioning, and impairment in social functioning. Mania often leads to hospitalization; by definition, hypomania does not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DSM-IV-TR criteria for major depression are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef70852 \" href=\"UTD.htm?17/21/17756\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/22\">",
"     22",
"    </a>",
"    ]. Diagnosis requires that at least five of nine symptoms are present during the same period and that one of the symptoms must be either depressed mood or loss of interest. Symptoms should be present daily or for most of the day, or nearly daily for at least two weeks.",
"   </p>",
"   <p>",
"    The symptoms must cause clinically significant distress or impairment in functioning, are not due to the direct effects of a substance (eg, drug abuse or medications) or a medical condition (eg, hypothyroidism), and do not occur within two months of the loss of a loved one (unless associated with pathologic grief). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31190?source=see_link\">",
"     \"Grief and bereavement\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Mixed state",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mixed state refers to the presence of both depressive and mood elevated (manic or hypomanic) symptoms simultaneously. It may thus occur with bipolar I or bipolar II disorder. The frequency of mixed states is estimated between 20 and 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/3\">",
"     3",
"    </a>",
"    ]. in a large cross-sectional study of patients with bipolar disease, 12 percent of 1380 patients with depressive symptoms had concurrent mania as defined by meeting all DSM-IV criteria for mania, but some manic symptoms were present in more than one half of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/24\">",
"     24",
"    </a>",
"    ]. The most common symptoms were irritability, racing or crowded thoughts, psychomotor agitation, or increased talkativeness concurrent with symptoms of depression. The presence of subsyndromal manic features correlated with more severe bipolar illness (earlier onset, rapid cycling, greater likelihood of suicide attempts).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bipolar disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar disorder is divided into three subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar I &ndash; a history of at least one episode of mania. Nearly all patients with bipolar I disorder also have episodes of major depression, but these are not required to make the diagnosis.",
"     </li>",
"     <li>",
"      Bipolar II &ndash; a history of at least one hypomanic episode plus at least one episode of major depression.",
"     </li>",
"     <li>",
"      Bipolar disorder not otherwise specified (NOS) &ndash; bipolar features that do not meet criteria for bipolar I or II disorder, eg, a history of episodes of hypomania with no history of major depression. This disorder is sometimes called bipolar spectrum disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients may have subthreshold bipolar disorder, defined as episodes of major depression and mood elevated symptoms that do not rise to the threshold of hypomania. A study of a community sample found that among 488 people identified with major depression, 41 percent had subthreshold bipolar disorder (and the remainder had pure unipolar major depressive disorder) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of bipolar I disorder is marked by relapses and remissions, often alternating manic with depressive episodes. Ninety percent of individuals who have one manic episode have another within five years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/11\">",
"     11",
"    </a>",
"    ]. Ninety percent of individuals with bipolar disorder have at least one psychiatric hospitalization and two-thirds have two or more hospitalizations in their lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/7\">",
"     7",
"    </a>",
"    ]. Bipolar II is less well studied, and the course is less well understood.",
"   </p>",
"   <p>",
"    Depressive symptoms are more frequent over the course of bipolar disorder than are manic symptoms, although the latter define the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients with bipolar I disorder experience depression three times more frequently than mania; patients with bipolar II disorder experience depression 37 times more frequently than hypomania [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypomanic episodes can disrupt the patient's functioning, but are less severe than the manic episodes that occur in bipolar I disorder. The level of functional impairment in patients with bipolar II disorder is closely linked to the severity of depressive episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The course of bipolar disorder is influenced by high rates of comorbid alcohol or substance abuse. Over a lifetime, almost two-thirds of patients with bipolar disorder will meet diagnostic criteria for an addictive disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Both the substance abuse and mood disorder should be addressed during therapy. Comorbid anxiety disorder is also common [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The course of illness is specified as rapid cycling if four or more mood episodes occurred during the previous 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Suicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The life expectancy of individuals with bipolar disorder is significantly reduced. Between 25 and 50 percent of people with this diagnosis attempt suicide, and 15 percent die by suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/30\">",
"     30",
"    </a>",
"    ]. This represents a significantly higher proportion of attempts among patients with bipolar disorder than among those with other Axis I diagnoses, including depression. A report from the Epidemiologic Catchment Area Database found that the lifetime rates of suicide attempts among people with bipolar disorder, unipolar depression, and other Axis I diagnoses were 29, 16, and 4 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for suicidal behavior in bipolar disease include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Personal or family history of suicidal behavior",
"     </li>",
"     <li>",
"      Severity and number of depressive episodes",
"     </li>",
"     <li>",
"      Alcohol or substance abuse",
"     </li>",
"     <li>",
"      Level of pessimism",
"     </li>",
"     <li>",
"      Level of impulsivity or aggression",
"     </li>",
"     <li>",
"      Younger age of onset",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Distinguishing unipolar and bipolar depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with bipolar disorder, particularly those with bipolar II disorder who do not exhibit overt symptoms of mania, are frequently misdiagnosed as having unipolar depression. Establishing the diagnosis of bipolar disorder is essential, in order to appropriately treat acute episodes and provide maintenance therapy. Mood stabilizing medications are indicated for most patients with depression and bipolar disorder to prevent mood swings to manic or hypomanic states. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=see_link\">",
"     \"Bipolar disorder in adults: Maintenance treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with bipolar, compared to unipolar, depression are more likely to have a family history of bipolar disorder and to have earlier age of onset [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients presenting with depression should be specifically asked about symptoms of mania or hypomania:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Have you experienced sustained periods of feeling uncharacteristically energetic?",
"     </li>",
"     <li>",
"      Have you had periods of not sleeping but not feeling tired?",
"     </li>",
"     <li>",
"      Have you felt that your thoughts were racing and couldn't be slowed down?",
"     </li>",
"     <li>",
"      Have you had periods where you were excessive in sexual interest, spending money, or taking unusual risks?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatively, patients could be asked to complete the Mood Disorders Questionnaire (MDQ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cyclothymia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclothymia is defined as a mood disturbance lasting at least two years, marked by periods of hypomanic symptoms and periods of depressive symptoms that do not meet criteria for a major depressive episode. Symptoms are usually present during cyclothymia, although remission may occur for periods lasting less than two months. Cyclothymia is usually treated with the same medications used to treat hypomania and mania. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many psychiatric conditions may mimic, and at times coexist with, bipolar disorder, including: schizophrenia; schizoaffective disorder; posttraumatic stress disorder; abuse of alcohol, cocaine, or amphetamines; and personality disorders such as narcissistic, borderline and histrionic personalities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/12,34\">",
"     12,34",
"    </a>",
"    ]. In addition, symptoms associated with several medical illnesses resemble manic episodes, including thyrotoxicosis, partial complex seizures, systemic lupus erythematosus, cerebrovascular accident, human immunodeficiency virus, tertiary syphilis, and steroid-induced mood symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concept of bipolar II disorder can potentially cover a wide spectrum of behaviors. Some have raised concerns about the effects of labeling common psychological or social phenomena as medical, and whether this could lead to overprescribing of psychoactive medications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete medical and psychiatric history and evaluation are necessary to establish the diagnosis of bipolar disorder, given the broad differential diagnosis when manic symptoms are present [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/11,12,34\">",
"     11,12,34",
"    </a>",
"    ]. Since bipolar depression and mixed states are associated with a significantly increased risk for suicide, assessment of suicidality is an essential component of evaluation.",
"   </p>",
"   <p>",
"    Patient evaluation should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical examination with a particular focus upon the neurologic and endocrine systems",
"     </li>",
"     <li>",
"      Observation for signs of abuse of alcohol or other substances",
"     </li>",
"     <li>",
"      Laboratory testing including thyroid stimulating hormone (TSH), complete blood count, chemistries, and urine toxicology for substances of abuse",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional testing, such as an electroencephalogram or brain imaging, is guided by relevant findings in the history and examination [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/11,12,36\">",
"     11,12,36",
"    </a>",
"    ]. Although neuroimaging studies show abnormalities in different areas of the brain, the only indication for imaging is to exclude other disorders that may present with symptoms akin to bipolar disorder, eg, central nervous system mass [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19639/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29416942\">",
"    <span class=\"h1\">",
"     GERIATRIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology, clinical features, and assessment of geriatric bipolar disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7545?source=see_link\">",
"     \"Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/5/4178?source=see_link\">",
"       \"Patient information: Bipolar disorder (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=see_link\">",
"       \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bipolar disorder is an illness characterized by periods of mood elevation; patients with bipolar I disorder have episodes of sustained mania, and often experience depressive episodes. Patients with bipolar II disorder have one or more major depressive episodes, with at least one hypomanic episode. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with bipolar disorder have a high rate of alcohol and substance abuse, as well as anxiety disorder. The rate of suicide attempts (between 25 and 50 percent) is higher than for other Axis I diagnoses. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations and diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary care physician should be alert to symptoms suggesting the possibility of bipolar II disorder in patients who are diagnosed with unipolar depression. Patients with bipolar disorder are more likely to have a family history of bipolar disorder, and present at an earlier age. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Distinguishing unipolar and bipolar depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of patients with suspected bipolar disorder should include an assessment of suicidality and evidence of substance abuse. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/1\">",
"      Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003; 64:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/2\">",
"      Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/3\">",
"      Benazzi F. Bipolar disorder--focus on bipolar II disorder and mixed depression. Lancet 2007; 369:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/4\">",
"      Das AK, Olfson M, Gameroff MJ, et al. Screening for bipolar disorder in a primary care practice. JAMA 2005; 293:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/5\">",
"      Hirschfeld RM, Holzer C, Calabrese JR, et al. Validity of the mood disorder questionnaire: a general population study. Am J Psychiatry 2003; 160:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/6\">",
"      Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/7\">",
"      Woods SW. The economic burden of bipolar disease. J Clin Psychiatry 2000; 61 Supp 13:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/8\">",
"      Hirschfeld RM, Cass AR, Holt DC, Carlson CA. Screening for bipolar disorder in patients treated for depression in a family medicine clinic. J Am Board Fam Pract 2005; 18:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/9\">",
"      Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000; 157:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/10\">",
"      Suppes T, Dennehy EB, Gibbons EW. The longitudinal course of bipolar disorder. J Clin Psychiatry 2000; 61 Suppl 9:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/11\">",
"      Hilty DM, Brady KT, Hales RE. A review of bipolar disorder among adults. Psychiatr Serv 1999; 50:201.",
"     </a>",
"    </li>",
"    <li>",
"     Sachs, G. Approach to the patient with elevated, expansive, or irritable mood. In: The MGH Guide to Psychiatry in Primary Care, Stern, TA, Herman, JB, Slavin, PL (Eds), McGraw-Hill, New York 1998. p.347.",
"    </li>",
"    <li>",
"     Robins, LN, Regier, DA. Psychiatric disorders in America: The Epidemiologic Catchment Area Study. New York, Free Press 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/14\">",
"      Potash JB, DePaulo JR Jr. Searching high and low: a review of the genetics of bipolar disorder. Bipolar Disord 2000; 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/15\">",
"      Craddock N, Jones I. Molecular genetics of bipolar disorder. Br J Psychiatry 2001; 178:S128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/16\">",
"      Craddock N, Jones I. Genetics of bipolar disorder. J Med Genet 1999; 36:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/17\">",
"      Kiesepp&auml; T, Partonen T, Haukka J, et al. High concordance of bipolar I disorder in a nationwide sample of twins. Am J Psychiatry 2004; 161:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/18\">",
"      Lichtenstein P, Yip BH, Bj&ouml;rk C, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009; 373:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/19\">",
"      Lin YM, Chao SC, Chen TM, et al. Association of functional polymorphisms of the human tryptophan hydroxylase 2 gene with risk for bipolar disorder in Han Chinese. Arch Gen Psychiatry 2007; 64:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/20\">",
"      Ferreira MA, O'Donovan MC, Meng YA, et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008; 40:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/21\">",
"      McQuillin A, Rizig M, Gurling HM. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet Genomics 2007; 17:605.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/23\">",
"      Keck PE Jr, McElroy SL, Arnold LM. Bipolar disorder. Med Clin North Am 2001; 85:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/24\">",
"      Goldberg JF, Perlis RH, Bowden CL, et al. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry 2009; 166:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/25\">",
"      Zimmermann P, Br&uuml;ckl T, Nocon A, et al. Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity. Arch Gen Psychiatry 2009; 66:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/26\">",
"      Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003; 60:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/27\">",
"      Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry 2005; 62:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/28\">",
"      Nease DE Jr, Volk RJ, Cass AR. Investigation of a severity-based classification of mood and anxiety symptoms in primary care patients. J Am Board Fam Pract 1999; 12:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/29\">",
"      Simon NM, Otto MW, Wisniewski SR, et al. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2004; 161:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/30\">",
"      Jamison KR. Suicide and bipolar disorder. J Clin Psychiatry 2000; 61 Suppl 9:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/31\">",
"      Chen YW, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other Axis I disorders. Biol Psychiatry 1996; 39:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/32\">",
"      Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7 Suppl 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/33\">",
"      Perlis RH, Brown E, Baker RW, Nierenberg AA. Clinical features of bipolar depression versus major depressive disorder in large multicenter trials. Am J Psychiatry 2006; 163:225.",
"     </a>",
"    </li>",
"    <li>",
"     Blazer, D. Mood disorders. In: Comprehensive Textbook of Psychiatry, volume VI, Kaplan, HI, Sadock, BJ (Eds), Williams and Wilkins, Baltimore 1995. p.1079.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/35\">",
"      Belmaker RH. Bipolar disorder. N Engl J Med 2004; 351:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/36\">",
"      Griswold KS, Pessar LF. Management of bipolar disorder. Am Fam Physician 2000; 62:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/37\">",
"      Hallahan B, Newell J, Soares JC, et al. Structural magnetic resonance imaging in bipolar disorder: an international collaborative mega-analysis of individual adult patient data. Biol Psychiatry 2011; 69:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19639/abstract/38\">",
"      Arnone D, Cavanagh J, Gerber D, et al. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. Br J Psychiatry 2009; 195:194.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 678 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-110.170.48.130-053DC9DE2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19639=[""].join("\n");
var outline_f19_11_19639=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mania",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Mixed state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bipolar disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Clinical course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Suicide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Distinguishing unipolar and bipolar depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cyclothymia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29416942\">",
"      GERIATRIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/678\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/678|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/3/20543\" title=\"algorithm 1\">",
"      Differential dx mood disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/678|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/53/3932\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for mania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/39/23164\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for hypomania",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/21/17756\" title=\"table 3\">",
"      DSM-IV-TR diagnostic criteria for major depression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/9/27802?source=related_link\">",
"      Bipolar disorder in adults: Maintenance treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7545?source=related_link\">",
"      Geriatric bipolar disorder: Epidemiology, clinical features, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31190?source=related_link\">",
"      Grief and bereavement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/5/4178?source=related_link\">",
"      Patient information: Bipolar disorder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/55/39796?source=related_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_11_19640="Pharmacology of antiviral drugs for influenza";
var content_f19_11_19640=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacology of antiviral drugs for influenza",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/11/19640/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/11/19640/contributors\">",
"     Kimon C Zachary, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/11/19640/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/11/19640/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/11/19640/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/11/19640/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/11/19640/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/11/19640/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two classes of antiviral drugs are available for the prevention and treatment of influenza:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The neuraminidase inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      , which are active against both influenza A and influenza B.",
"     </li>",
"     <li>",
"      The adamantanes,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"       rimantadine",
"      </a>",
"      , which are only active against influenza A. Due to a marked increase in resistant isolates, these agents should NOT be used in the United States for influenza prophylaxis or treatment except in selected circumstances, which are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link&amp;anchor=H20#H20\">",
"       \"Prevention of seasonal influenza in adults\", section on 'Choice of antiviral drug'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link&amp;anchor=H18#H18\">",
"       \"Treatment of seasonal influenza in adults\", section on 'Choice of antiviral drug'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pharmacologic issues related to these drugs will be reviewed here. Their role in the prevention and treatment of influenza are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=see_link\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39032?source=see_link\">",
"     \"Treatment and prevention of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEURAMINIDASE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     Zanamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    are structurally related drugs that have been approved by the US Food and Drug Administration (FDA) for the prophylaxis and treatment of influenza.",
"   </p>",
"   <p>",
"    In addition to their activity against current influenza A and influenza B strains, they are also active against the strain that caused the 1918 pandemic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/1\">",
"     1",
"    </a>",
"    ] and against avian influenza A strains [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14090?source=see_link\">",
"     \"Epidemiology, transmission, and pathogenesis of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A 2003 meta-analysis of 17 treatment and seven prevention trials concluded that these drugs reduced the median duration of symptoms by approximately one day and, depending upon the population studied and strategy adopted, reduced the odds of developing influenza by 70 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza hemagglutinin is a surface glycoprotein that binds to sialic acid residues on respiratory epithelial cell surface glycoproteins. This interaction is necessary for the initiation of infection. After viral replication, progeny virions are also bound to the host cell. Neuraminidase inhibitors interfere with the release of progeny influenza virus from infected cells, thereby preventing new rounds of infection&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     Zanamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    are sialic acid analogs that competitively inhibit neuraminidase on the surface of both influenza A and B. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    are only active against influenza A. Cleavage of the terminal sialic acid residue on the host cell receptor prevents infection by destroying the receptor that is recognized by the viral hemagglutinin. This minimizes the release of virus from infected cells, thereby diminishing the spread of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     Zanamivir",
"    </a>",
"    is administered as an inhaled powder and has poor oral bioavailability. Approximately 15 percent of inhaled zanamivir is deposited in the bronchi and lungs with the remainder staying in the oropharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/6\">",
"     6",
"    </a>",
"    ]. It is highly concentrated in the respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/5\">",
"     5",
"    </a>",
"    ]. Excretion is primarily renal, but given limited systemic bioavailability, there is no need to modify the dose in patients with renal insufficiency. The pulmonary half-life is 2.8 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/7\">",
"     7",
"    </a>",
"    ]. Zanamivir inhalation powder should not be reconstituted in any liquid formulation and is not recommended for use in nebulizers or mechanical ventilators [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    phosphate is orally administered and is available as a capsule or powder for liquid suspension that is rapidly metabolized to the active form, oseltamivir carboxylate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/9\">",
"     9",
"    </a>",
"    ]. A single 100 mg dose yields a peak plasma concentration of 250",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    with an elimination half-life of approximately eight hours [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/10\">",
"     10",
"    </a>",
"    ]. Food does not affect peak concentration or overall systemic exposure. Elimination is primarily renal, and dose reduction is recommended for patients with an estimated creatinine clearance of less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a small study of critically ill patients with 2009-2010 pandemic H1N1 influenza A infection,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    was well absorbed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/11\">",
"     11",
"    </a>",
"    ]. The usual dose of 75 mg twice daily resulted in plasma concentrations of the active carboxylate metabolite that were comparable to those observed among ambulatory patients in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of the neuraminidase inhibitors for the prevention and treatment of influenza is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=see_link\">",
"     \"Influenza and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39032?source=see_link\">",
"     \"Treatment and prevention of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    are generally well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116594844\">",
"    <span class=\"h3\">",
"     Zanamivir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following potential adverse effects should be considered before initiating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The delivery system for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      (inhaled dry powder) has raised concerns about use in patients with pulmonary disease, such as chronic obstructive pulmonary disease (COPD) or asthma. Respiratory distress associated with zanamivir has been reported in a patient presenting with an exacerbation of COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/12\">",
"       12",
"      </a>",
"      ]. The safety of this drug in patients with severe COPD or asthma has not been established, and data from a placebo-controlled trial enrolling such patients suggest an increased risk of a substantial (greater than 20 percent) reduction in FEV1 in zanamivir recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       Zanamivir",
"      </a>",
"      is generally not recommended for individuals with underlying respiratory disease such as asthma or chronic obstructive pulmonary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. If it is used in such patients, a fast-acting bronchodilator should be readily available [",
"      <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       Zanamivir",
"      </a>",
"      inhalation powder is",
"      <strong>",
"       not",
"      </strong>",
"      recommended for use in nebulizers or mechanical ventilators since the lactose carrier can clog ventilator tubing [",
"      <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Concerns have also been raised about the ease of use of the Diskhaler device currently provided by the manufacturer to deliver the drug. In particular, elderly patients may have significant difficulty using the device correctly [",
"      <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vasovagal-like episodes have been reported soon after the inhalation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      in post-marketing reports [",
"      <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       Zanamivir",
"      </a>",
"      should be avoided in patients with allergy to milk proteins, given the presence of the lactose carrier [",
"      <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116594851\">",
"    <span class=\"h3\">",
"     Oseltamivir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common toxicities reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    have been nausea and vomiting, which occur in approximately 15 percent of recipients. These side effects are usually mild and limited to the first day or two of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/10,20-23\">",
"     10,20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postmarketing reports have identified rare but serious adverse events in patients with influenza who are taking neuraminidase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. These events include neuropsychiatric effects (delirium, hallucinations, confusion, abnormal behavior, convulsions, and encephalitis), death, and severe skin reactions (including toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/27\">",
"     27",
"    </a>",
"    ]. Most of the reports of neuropsychiatric events involved",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and occurred in children in Japan, where the use of neuraminidase inhibitors is widespread [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/28\">",
"     28",
"    </a>",
"    ]. The events often had an abrupt onset and rapid resolution [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/26\">",
"     26",
"    </a>",
"    ]. A causal association between neuraminidase inhibitors and these events has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. Some of the adverse events may have been related to influenza infection rather than treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H7#H7\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Rare adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADAMANTANES",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    are closely related adamantanes (also called M2 inhibitors). They are active only against influenza A. These drugs appear equally effective, although the widespread emergence of adamantane-resistant influenza A strains has limited their role in clinical practice. These agents should NOT be used for influenza prophylaxis or treatment except in selected circumstances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link&amp;anchor=H20#H20\">",
"     \"Prevention of seasonal influenza in adults\", section on 'Choice of antiviral drug'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of seasonal influenza in adults\", section on 'Choice of antiviral drug'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    target the M2 protein of influenza A. This protein forms a proton channel in the viral membrane that is essential for efficient viral replication [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consistent with the importance of the M2 protein is the observation that resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    is mediated by single nucleotide changes involving the transmembrane portion of the molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Such mutations confer cross-resistance between the adamantanes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/43\">",
"     43",
"    </a>",
"    ]. The rate of spontaneous mutations resulting in drug resistance in tissue culture is quite high, between 1:1000 and 1:10,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link&amp;anchor=H12#H12\">",
"     \"Prevention of seasonal influenza in adults\", section on 'Adamantane resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Drug metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    is primarily excreted unchanged in the urine. In patients with an estimated creatinine clearance of less than 50",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    the daily dose should be reduced from the usual adult dose of 100 mg twice daily to 100 mg daily; a similar dose reduction is recommended for patients older than 65 years (",
"    <a class=\"graphic graphic_table graphicRef50350 \" href=\"UTD.htm?14/32/14860\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     \"Amantadine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     Rimantadine",
"    </a>",
"    is extensively metabolized in the liver, and three hydroxylated metabolites have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/44\">",
"     44",
"    </a>",
"    ]. Dose reduction from 100 mg twice daily to 100 mg daily is recommended for patients with severe hepatic dysfunction, renal failure (creatinine clearance &lt;10",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    and elderly patients (",
"    <a class=\"graphic graphic_table graphicRef50350 \" href=\"UTD.htm?14/32/14860\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     \"Rimantadine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    are generally well tolerated, especially in younger, healthy adults. However, central nervous system (CNS) side effects are well described with amantadine, including anxiety, insomnia, impaired thinking, confusion, lightheadedness, and hallucinations. These side effects appear to be related to peak drug concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/45\">",
"     45",
"    </a>",
"    ] and are more common in elderly patients.",
"   </p>",
"   <p>",
"    Studies in young adults report a discontinuation rate of 13 to 17 percent, largely attributable to CNS toxicity. Discontinuation was significantly higher than the 4 to 8 percent withdrawal rate with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Similar CNS side effects have been described with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    but at a considerably lower rate, resulting in withdrawal rates similar to that of placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/46,48\">",
"     46,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    may be associated with an increased rate of seizure activity in patients with a history of epilepsy, and should be used with caution in such individuals. Amantadine has anticholinergic effects that can cause dry mouth and mydriasis; as a result, it is contraindicated in patients with untreated angle closure glaucoma. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     \"Amantadine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     \"Rimantadine: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7239911\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some instances of antiviral drug resistance among influenza viruses have occurred during antiviral therapy, some resistant influenza strains have spread widely in the absence of such drug pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/49\">",
"     49",
"    </a>",
"    ]. Adamantane-resistant H3N2 influenza A viruses have circulated globally since 2003,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant seasonal H1N1 influenza A viruses since 2007, and adamantane-resistant pandemic H1N1 influenza A viruses since 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/49\">",
"     49",
"    </a>",
"    ]. Resistance to the adamantanes generally occurs more readily than resistance to the neuraminidase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/50\">",
"     50",
"    </a>",
"    ]. Antiviral drug resistance among influenza viruses is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39880?source=see_link\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H10#H10\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Antiviral resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment and prevention of pandemic H1N1 influenza ('swine influenza')\", section on 'Drug resistance'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39032?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and prevention of avian influenza\", section on 'Drug resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;No trials have been performed to assess the safety or efficacy of antiviral drugs during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/51\">",
"     51",
"    </a>",
"    ]. All four approved drugs are FDA pregnancy category C, indicating that their effects in pregnant women and fetuses have not been well defined. &nbsp;",
"   </p>",
"   <p>",
"    Animal studies have shown no evidence of adverse outcomes in the offspring of animals exposed to the neuraminidase inhibitors during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Among 61 women who took",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    during pregnancy, one case of trisomy 21 and one case of anencephaly were reported in their infants, although neither case was thought to be causally linked to drug exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/53\">",
"     53",
"    </a>",
"    ]. Ten of the 61 pregnancies ended in abortion, six of which were therapeutic. Three pregnant women were exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    during clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/52,54\">",
"     52,54",
"    </a>",
"    ]. Of these, one ended in spontaneous abortion, one in elective termination, and one resulted in a healthy infant.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    appear to be teratogenic and embryotoxic in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/55\">",
"     55",
"    </a>",
"    ]. There are no adequate studies of either drug in pregnant women, but skeletal and cardiovascular abnormalities have been described in an infant exposed to amantadine during the first trimester of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Levels exceeding 90 percent of the inhibitory concentration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and its active metabolite, oseltamivir carboxylate, were detected in the cord blood of a neonate born to a woman with severe influenza who was being treated with oseltamivir 150 mg orally twice daily, which is twice the usual dose [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/57\">",
"     57",
"    </a>",
"    ]. In contrast, in a study that assessed the metabolism and transplacental transfer of oseltamivir in an ex vivo human placenta model, oseltamivir and its metabolite were only detected in the placentas in which extremely high doses of oseltamivir were administered (20- to 830-fold higher than therapeutic dosing) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19640/abstract/58\">",
"     58",
"    </a>",
"    ]. Further study is necessary to evaluate whether oseltamivir reaches substantial levels in the fetal circulation.",
"   </p>",
"   <p>",
"    <br/>",
"    The indications for influenza prophylaxis and treatment in pregnant women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=see_link\">",
"     \"Influenza and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=see_link&amp;anchor=H19#H19\">",
"     \"Prevention of seasonal influenza in adults\", section on 'Pregnancy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of seasonal influenza in adults\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The neuraminidase inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      , are active against influenza A and B and are the first-line agents for the prophylaxis and treatment of influenza. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The adamantanes,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"       rimantadine",
"      </a>",
"      , are only active against influenza A. Because of a marked increase in resistant isolates, these agents should NOT be used for influenza prophylaxis or treatment except in selected circumstances. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuraminidase inhibitors interfere with the release of progeny influenza virus from infected cells, thereby preventing new rounds of infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"       Amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=see_link\">",
"       rimantadine",
"      </a>",
"      target the M2 protein of influenza A, which forms a proton channel in the viral membrane that is essential for efficient viral replication. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       Zanamivir",
"      </a>",
"      is administered as an inhaled powder.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       Oseltamivir",
"      </a>",
"      is orally administered and is available as a capsule or powder for liquid suspension. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      are generally well tolerated. Zanamivir is not recommended for individuals with underlying respiratory disease such as asthma or chronic obstructive pulmonary disease. Cases of neuropsychiatric effects leading to fatal outcomes have been reported with oseltamivir, particularly in children in Japan, although the causal relationship remains unclear. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although some instances of antiviral drug resistance among influenza viruses have occurred in the setting of drug pressure (ie, during antiviral therapy), some resistant influenza strains have spread widely in the absence of drug pressure. As examples, adamantane-resistant H3N2 influenza A viruses have circulated globally since 2003,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      -resistant seasonal H1N1 influenza A viruses since 2007, and adamantane-resistant pandemic H1N1 influenza A viruses since 2009. (See",
"      <a class=\"local\" href=\"#H7239911\">",
"       'Resistance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/1\">",
"      Tumpey TM, Garc&iacute;a-Sastre A, Mikulasova A, et al. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A 2002; 99:13849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/2\">",
"      Leneva IA, Goloubeva O, Fenton RJ, et al. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother 2001; 45:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/3\">",
"      Leneva IA, Roberts N, Govorkova EA, et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000; 48:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/4\">",
"      Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003; 326:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/5\">",
"      Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/6\">",
"      Cheer SM, Wagstaff AJ. Zanamivir: an update of its use in influenza. Drugs 2002; 62:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/7\">",
"      Peng AW, Milleri S, Stein DS. Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. Antimicrob Agents Chemother 2000; 44:1974.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration. MedWatch Safety Alert. Relenza (zanamivir) inhalation powder. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm186081.htm (Accessed on October 09, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/9\">",
"      Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 2010; 65 Suppl 2:ii5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/10\">",
"      Bardsley-Elliot A, Noble S. Oseltamivir. Drugs 1999; 58:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/11\">",
"      Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010; 182:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/12\">",
"      Williamson JC, Pegram PS. Respiratory distress associated with zanamivir. N Engl J Med 2000; 342:661.",
"     </a>",
"    </li>",
"    <li>",
"     Relenza prescribing information. file://us.gsk.com/products/assets/us_relenza.pdf (Accessed on October 08, 2008).",
"    </li>",
"    <li>",
"     file://www.fda.gov/cder/news/relenza/default.htm (Accessed on October 06, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/15\">",
"      Kiatboonsri S, Kiatboonsri C, Theerawit P. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis 2010; 50:620.",
"     </a>",
"    </li>",
"    <li>",
"     US Centers for Disease Control and Prevention. Interim guidance on the use of influenza antiviral agents during the 2010-2011 influenza season file://www.cdc.ov/flu/professionals/antivirals/guidance/summary.htm (Accessed on December 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/17\">",
"      Diggory P, Fernandez C, Humphrey A, et al. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ 2001; 322:577.",
"     </a>",
"    </li>",
"    <li>",
"     Relenza (zanamivir) inhalation powder: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) &ndash; December 2010. file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm239917.htm (Accessed on February 10, 2011).",
"    </li>",
"    <li>",
"     Relenza (zanamivir) inhalation powder: safety labeling changes approved by the FDA Center for Drug Evaluation and Research (CDER) - December 2011. file://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm239917.htm (Accessed on January 25, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/20\">",
"      Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/21\">",
"      Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/22\">",
"      Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/23\">",
"      Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341:1336.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. Tamiflu pediatric adverse events: Questions and answers www.fda.gov/cder/drug/infopage/tamiflu/QA20051117.htm (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. 2008 Safety alerts for drugs, biologics, medical devices, and dietary supplements. Tamiflu (oseltamivir phosphate). file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm095044.htm (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. 2008 Safety alerts for drugs, biologics, medical devices, and dietary supplements. Relenza (zanamivir). file://www.fda.gov/Safety/MedWatch/Safetyinformation/SafetyAlertsforHumanMedicalProducts/ucm094982.htm (Accessed on September 06, 2011).",
"    </li>",
"    <li>",
"     Tamiflu (oseltamivir) prescribing information, 2011. www.gene.com/gene/products/information/tamiflu/pdf/pi.pdf (Accessed on May 02, 2012).",
"    </li>",
"    <li>",
"     Pollack A. Childhood deaths in Japan bring new look at flu drug. New York Times, November 18, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/29\">",
"      Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health 2009; 21:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/30\">",
"      Lindemann L, Jacobsen H, Schuhbauer D, et al. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite. Eur J Pharmacol 2010; 628:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/31\">",
"      Hoffmann G, Funk C, Fowler S, et al. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother 2009; 53:4753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/32\">",
"      Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract 2009; 63:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/33\">",
"      Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008; 31:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/34\">",
"      Terada K, Kawai Y, Monju A, et al. Adolescent jump case in Japan associated with influenza but not oseltamivir. Pediatr Infect Dis J 2008; 27:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/35\">",
"      Hara K, Tanabe T, Nakano R, et al. Clinical characteristics of children with abnormal behaviors associated with influenza infection. J Jpn Pediatr Soc 2007; 111:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/36\">",
"      Wang YH, Huang YC, Chang LY, et al. Clinical characteristics of children with influenza A virus infection requiring hospitalization. J Microbiol Immunol Infect 2003; 36:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/37\">",
"      Huang YC, Li WC, Tsao KC, et al. Influenza-associated central nervous system dysfunction in Taiwanese children: clinical characteristics and outcomes with and without administration of oseltamivir. Pediatr Infect Dis J 2009; 28:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/38\">",
"      Tanabe T, Hara K, Nakajima M, et al. Oseltamivir treatment for children showing abnormal behavior during influenza virus infection. Brain Dev 2010; 32:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/39\">",
"      Bui M, Whittaker G, Helenius A. Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins. J Virol 1996; 70:8391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/40\">",
"      Tosteson MT, Pinto LH, Holsinger LJ, Lamb RA. Reconstitution of the influenza virus M2 ion channel in lipid bilayers. J Membr Biol 1994; 142:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/41\">",
"      Takeda M, Pekosz A, Shuck K, et al. Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture. J Virol 2002; 76:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/42\">",
"      Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/43\">",
"      Belshe RB, Smith MH, Hall CB, et al. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1988; 62:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/44\">",
"      Hayden FG, Minocha A, Spyker DA, Hoffman HE. Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob Agents Chemother 1985; 28:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/45\">",
"      Hirsch MS, Swartz MN. Drug therapy: antiviral agents (first of two parts). N Engl J Med 1980; 302:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/46\">",
"      Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/47\">",
"      Pettersson RF, Hellstr&ouml;m PE, Penttinen K, et al. Evaluation of amantadine in the prophylaxis of influenza A (H1N1) virus infection: a controlled field trial among young adults and high-risk patients. J Infect Dis 1980; 142:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/48\">",
"      Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother 1995; 39:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/49\">",
"      Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis 2011; 203:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/50\">",
"      Dolin R. Resistance to neuraminidase inhibitors. Clin Infect Dis 2011; 52:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/51\">",
"      Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/52\">",
"      Rasmussen SA, Jamieson DJ, Bresee JS. Pandemic influenza and pregnant women. Emerg Infect Dis 2008; 14:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/53\">",
"      Ward P, Small I, Smith J, et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55 Suppl 1:i5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/54\">",
"      Freund B, Gravenstein S, Elliott M, Miller I. Zanamivir: a review of clinical safety. Drug Saf 1999; 21:267.",
"     </a>",
"    </li>",
"    <li>",
"     Hayden FG. Antiviral drugs (other than antiretrovirals). In: Principles and Practice of Infectious Diseases, 6th ed, Mandell GL, Bennett JE, Dolin R (Eds), Elsevier, Philadelphia 2005. p.514.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/56\">",
"      Pandit PB, Chitayat D, Jefferies AL, et al. Tibial hemimelia and tetralogy of Fallot associated with first trimester exposure to amantadine. Reprod Toxicol 1994; 8:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/57\">",
"      Meijer WJ, Bruinse HW, van den Broek MP, et al. Oseltamivir and its active metabolite cross the placenta at significant levels. Clin Infect Dis 2012; 54:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19640/abstract/58\">",
"      Worley KC, Roberts SW, Bawdon RE. The metabolism and transplacental transfer of oseltamivir in the ex vivo human model. Infect Dis Obstet Gynecol 2008; 2008:927574.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7008 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19640=[""].join("\n");
var outline_f19_11_19640=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEURAMINIDASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H116594844\">",
"      - Zanamivir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H116594851\">",
"      - Oseltamivir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADAMANTANES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Drug metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7239911\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7008\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7008|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/32/14860\" title=\"table 1\">",
"      Antivirals for influenza",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=related_link\">",
"      Amantadine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/60/39880?source=related_link\">",
"      Antiviral drug resistance among seasonal influenza viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14090?source=related_link\">",
"      Epidemiology, transmission, and pathogenesis of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/25/35224?source=related_link\">",
"      Influenza and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/10/30885?source=related_link\">",
"      Rimantadine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39032?source=related_link\">",
"      Treatment and prevention of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38234?source=related_link\">",
"      Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_11_19641="Allergic contact dermatitis histopathology";
var content_f19_11_19641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Epidermal spongiosis and spongiotic vesicles are present in this biopsy taken from a patient with poison ivy. Infiltrating lymphocytes are apparent in the epidermis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19641=[""].join("\n");
var outline_f19_11_19641=null;
var title_f19_11_19642="Status epilepticus in adults";
var content_f19_11_19642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Status epilepticus in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/11/19642/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/11/19642/contributors\">",
"     Mark M Stecker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/11/19642/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/11/19642/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/11/19642/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/11/19642/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/11/19642/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although exact definitions vary, the term status epilepticus generally refers to the occurrence of a single unremitting seizure with a duration longer than 5 to 10 minutes or frequent clinical seizures without an interictal return to the baseline clinical state [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic evaluation and clinical management of status epilepticus will be discussed here. The management of chronic epilepsy, the actions of antiepileptic drugs, and the management of status epilepticus in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link\">",
"     \"Management of status epilepticus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that there are 100,000 to 200,000 episodes of status epilepticus in the United States annually [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Refractory status epilepticus, defined as ongoing seizures following first- and second-line drug therapy, was noted in nearly 30 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/5\">",
"     5",
"    </a>",
"    ] to 43 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/6\">",
"     6",
"    </a>",
"    ] percent of patients with status epilepticus. Although not associated with increased mortality, refractory status epilepticus was linked to prolonged hospitalization and poorer functional outcomes. Encephalitis was associated significantly more often with refractory than with nonrefractory status epilepticus (22 versus 4 percent, respectively). In contrast, inadequate serum levels of antiepileptic drugs (AEDs) were associated significantly more often with nonrefractory than with refractory status epilepticus (28 versus 0 percent, respectively). Also, generalized tonic-clonic status was less likely to be refractory than nonconvulsive or focal motor status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal management of status epilepticus requires identification and correction, if possible, of any predisposing factors that are present. Virtually any acute or chronic brain injury, as well as a number of toxic-metabolic insults, can cause status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Some of the more common predisposing factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiepileptic drug noncompliance or discontinuation",
"     </li>",
"     <li>",
"      Withdrawal syndromes associated with the discontinuation of alcohol, barbiturates,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      , or benzodiazepines (particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Acute structural injury (eg, brain tumor or cerebral metastasis, stroke, head trauma, subarachnoid hemorrhage, cerebral anoxia or hypoxia) or infection (encephalitis, meningitis, abscess).",
"     </li>",
"     <li>",
"      Remote or longstanding structural injury (eg, prior head injury, cerebral palsy, previous neurosurgery, perinatal cerebral ischemia, arteriovenous malformations)",
"     </li>",
"     <li>",
"      Metabolic abnormalities (eg, hypoglycemia, hepatic encephalopathy, uremia, pyridoxine deficiency, hyponatremia, hyperglycemia, hypocalcemia, hypomagnesemia)",
"     </li>",
"     <li>",
"      Use of, or overdose with drugs that lower the seizure threshold (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      , imipenem, high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      , quinolone antibiotics,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      , tricyclic antidepressants,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"       flumazenil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      , metrizamide, and, to a lesser extent, phenothiazines)",
"     </li>",
"     <li>",
"      Chronic epilepsy; status epilepticus may represent part of a patient's underlying epileptic syndrome (as with the Landau-Kleffner syndrome or Rasmussen's encephalitis), or may be associated with any of the generalized epilepsies",
"     </li>",
"     <li>",
"      New onset refractory status epilepticus (NORSE) is a syndrome described in a number of reports of patients who present with severe generalized seizures of unclear etiology in the setting of a prodromal febrile illness [",
"      <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/8-12\">",
"       8-12",
"      </a>",
"      ]. Patients typically do not respond to AEDs and mortality and morbidity are high.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AND OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality rate for adults who present with a first episode of status epilepticus is roughly 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/4,13\">",
"     4,13",
"    </a>",
"    ]. Estimates vary widely, mainly as a function of the underlying etiology and whether status epilepticus following cerebral anoxia is included in the study [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/1,14-16\">",
"     1,14-16",
"    </a>",
"    ]. The mortality for status epilepticus after anoxia ranges from 69 to 81 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/4,7,17\">",
"     4,7,17",
"    </a>",
"    ]. While etiology is the most important predictor of outcome, older age, medical comorbidity, and high initial APACHE-II scores (a prognostic scoring system for ICU patients based on underlying disease, chronic conditions, and physiologic variables) are also independent risk factors for mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/16,18-21\">",
"     16,18-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of the other underlying causes of status epilepticus (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Etiology'",
"    </a>",
"    above) are associated with significant morbidity and mortality, even in the absence of seizures. In one series, 89 percent of deaths in patients with status epilepticus were attributed to the underlying etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/22\">",
"     22",
"    </a>",
"    ]. Another study suggested that acute symptomatic status epilepticus is associated with a six-fold increased risk of mortality compared to status epilepticus arising from chronic epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/23\">",
"     23",
"    </a>",
"    ]. &nbsp;Mortality is also lower in individuals who have previously survived an episode of status epilepticus (4.8 versus 15.6 percent in one study), again suggesting that the underlying etiology is a major determinant of outcome in status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mortality of status epilepticus is in part due to the metabolic stress of repeated muscular convulsions. Rhabdomyolysis, lactic acidosis, aspiration pneumonitis, neurogenic pulmonary edema, and respiratory failure may complicate convulsions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/1\">",
"     1",
"    </a>",
"    ]. In one analysis, patients who received mechanical ventilation had a three-fold increase in mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/16\">",
"     16",
"    </a>",
"    ]. Cardiac injury due to massive release of catecholamines may also contribute to injury [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26952?source=see_link&amp;anchor=H140695105#H140695105\">",
"     \"Cardiac complications of stroke\", section on 'Neurogenic cardiac damage'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, neuronal death can occur under certain circumstances after as little as 30 to 60 minutes of continuous seizure activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. The pathologic hallmark of this phenomenon, cortical laminar necrosis, may also be seen on brain MRI as a persistent, high intensity lesion on T2 or diffusion-weighted images, which follows the gyral anatomy of the cerebral cortex [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Clinically, this effect manifests in increasing neurologic morbidity with increasing seizure duration, even after the effects of etiology are eliminated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/27,31\">",
"     27,31",
"    </a>",
"    ]. Consequently, survivors of status epilepticus are at significant risk for recurrent seizures, and in some series, 10 to 50 percent are left with disabling neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/23,32,33\">",
"     23,32,33",
"    </a>",
"    ]. Longer seizure duration and status epilepticus in the setting of acute neurologic insult are risk factors for long-term neurologic disability.",
"   </p>",
"   <p>",
"    Status epilepticus will recur in approximately one-third of patients, according to one population-based study that followed patients for 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/34\">",
"     34",
"    </a>",
"    ]. When patients with progressive neurologic disease were excluded, the risk was 25 percent and was similar among other etiologic subgroups. Female gender and a failure to respond to the first drug administered for status epilepticus were risk factors for recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of status epilepticus is often straightforward, but may be more complicated when symptoms are continuous and affect focal cognitive functions like language. The diagnosis of status epilepticus rests primarily upon the neurologic examination and the electroencephalogram (EEG).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the diagnosis of tonic-clonic status epilepticus may be obvious, a neurologic examination can be critical in making the diagnosis in nonconvulsive status epilepticus. Particularly important are assessment of the level of consciousness, observations for automatic movements or myoclonus, and any asymmetric features on examination that may indicate a focal structural lesion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link&amp;anchor=H5#H5\">",
"     \"Stupor and coma in adults\", section on 'Neurologic examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Electroencephalogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The EEG is an extremely valuable tool in evaluating the patient with suspected status epilepticus. An EEG that reveals continuous seizure activity is diagnostic of status epilepticus. However, there are some limitations to the use of the EEG in this context [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clear ictal activity may not be seen during simple partial status epilepticus",
"     </li>",
"     <li>",
"      Some ictal EEG patterns are difficult to recognize or are controversial",
"     </li>",
"     <li>",
"      An EEG obtained over a short period of time and between seizures can miss intermittent ictal activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many cases of status epilepticus can be diagnosed on the basis of the neurologic examination alone, but EEG data are invaluable in diagnosing complex cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27863?source=see_link\">",
"     \"Clinical neurophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain EEG patterns in unresponsive patients are diagnostic of status epilepticus, including patterns that show temporal evolution. The meaning of other patterns, such as periodic lateralized epileptiform discharges (PLEDS) (",
"    <a class=\"graphic graphic_waveform graphicRef62133 \" href=\"UTD.htm?14/26/14761\">",
"     waveform 1",
"    </a>",
"    ), remains controversial, although aggressive pharmacologic treatment in a patient whose EEG shows only PLEDS without evolution and whose examination reveals no clinical seizures should generally be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/36\">",
"     36",
"    </a>",
"    ]. Continuous EEG recordings may be helpful if the initial study is not diagnostic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Single photon emission computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single photon emission computed tomography (SPECT) may demonstrate areas of increased perfusion during status epilepticus that can persist for weeks after the termination of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/37\">",
"     37",
"    </a>",
"    ]. SPECT may be helpful in diagnosing status epilepticus when the EEG is equivocal. However, good studies of sensitivity and specificity are not available, and results should be interpreted in conjunction with clinical and EEG findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is the best tool to reveal the structural lesions that may trigger status epilepticus, but MRI is not a first-line test for diagnosing status epilepticus. However, MRI may reveal areas of increased signal intensity on FLAIR, T2-, or diffusion-weighted images in the presence of status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. These findings are believed to represent seizure-induced cellular edema and are seen in cortical and limbic structures, particularly the hippocampus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/40\">",
"     40",
"    </a>",
"    ]. They may persist for days to weeks, especially if seizures are prolonged, and either ultimately resolve or evolve into focal atrophy and sclerosis. These lesions are nonspecific and can be associated with many other processes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classifying the type of status epilepticus is important because it is a major factor in determining morbidity and, therefore, the aggressiveness of treatment that is required; generalized tonic-clonic or partial-complex status epilepticus poses the greatest risk. The three most common forms of status epilepticus are:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Simple partial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple partial status epilepticus is characterized by continuous or repeated focal motor seizures (eg, twitching of one thumb), focal sensory symptoms (eg, the sensation of flashing lights in one visual field), or cognitive symptoms (eg, aphasia) without impaired consciousness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Complex partial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex partial status (nonconvulsive) epilepticus is characterized by continuous or repeated episodes of focal motor, sensory, or cognitive symptoms with impaired consciousness, and should be considered in the differential diagnosis of acute confusional states [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/41\">",
"     41",
"    </a>",
"    ]. Other symptoms, such as automatisms and behavioral disturbances, may also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Generalized tonic-clonic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized tonic-clonic status epilepticus is always associated with impaired consciousness. Tonic-clonic seizures may be the initial manifestation of status epilepticus, or may represent secondary generalization from other seizure types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Less common varieties",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the three major types of status epilepticus listed above, there are a number of less common but important forms to recognize:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Absence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absence (petit mal) status epilepticus is characterized by altered awareness, but not necessarily unconsciousness. Patients are typically confused or stuporous, and there may be associated myoclonus, eye blinking, perseveration, altered motor performance, language difficulty, or other symptoms. Absence status epilepticus typically occurs in patients with chronic idiopathic epilepsy and frequently requires EEG for confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Myoclonic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonic status epilepticus is characterized by frequent myoclonic jerks, usually in the setting of altered mental status. This typically occurs in patients with one of the generalized epilepsies, such as juvenile myoclonic epilepsy. The term has also been applied by some authors to the myoclonus seen in the patient who has experienced global cerebral ischemia. However, this myoclonus should not be considered in the same category as myoclonic status epilepticus unless EEG recordings demonstrate actual seizure activity and not simply a burst-suppression pattern. Overall, patients with myoclonus and altered consciousness are far more likely to be suffering from a metabolic encephalopathy (particularly uremic or hepatic encephalopathy) than from true myoclonic status epilepticus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Psychogenic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although relatively rare, psychogenic status epilepticus should be considered in situations where there are bilateral motor movements with preserved consciousness. An EEG recording during one of the patient's typical clinical events can help establish this diagnosis, although the EEG may also appear relatively normal during simple partial status epilepticus.",
"   </p>",
"   <p>",
"    Although prolactin levels drawn shortly after the onset of a seizure may help differentiate epileptic and non-epileptic events, prolactin levels normalize during prolonged seizures and so are not helpful in the diagnosis of status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Creatine kinase levels are typically markedly elevated after generalized convulsive epileptic seizures and are only rarely and mildly elevated after psychogenic seizures even when motor features are pronounced [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/43\">",
"     43",
"    </a>",
"    ]. This test is of most value when motor features are very prominent. Also, there may be a delay in peak concentrations, limiting the value of this test somewhat in the emergency setting.",
"   </p>",
"   <p>",
"    Psychogenic nonepileptic seizures and psychogenic status epilepticus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=see_link\">",
"     \"Psychogenic nonepileptic seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four main categories of drugs used to treat status epilepticus: benzodiazepines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    ), barbiturates, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/2\">",
"     2",
"    </a>",
"    ]. Other treatments with drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/35/24117?source=see_link\">",
"     paraldehyde",
"    </a>",
"    (which is no longer available in the United States for intravenous infusion),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/26/5542?source=see_link\">",
"     chloral hydrate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/34/15908?source=see_link\">",
"     etomidate",
"    </a>",
"    are less efficacious or less well studied and should",
"    <strong>",
"     not",
"    </strong>",
"    be considered part of the routine management of status epilepticus. Similarly, general anesthesia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/63/17397?source=see_link\">",
"     isoflurane",
"    </a>",
"    or other inhalational agents may be temporarily effective in stopping seizures but is used only in extreme circumstances because of logistical problems. Other agents such as chlormethiazole are used in other countries but are not available in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines remain the first-line treatment for status epilepticus because they can rapidly control seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/45\">",
"     45",
"    </a>",
"    ]. A number of studies have addressed the different uses and pharmacology of the three most commonly used benzodiazepines for status epilepticus:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    . All are thought to increase chloride conductance in central nervous system GABA(A) receptors and thus decrease neuronal excitability [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Diazepam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     Diazepam",
"    </a>",
"    has a high lipid solubility and therefore an ability to rapidly cross the blood-brain barrier; it is highly effective in rapidly terminating seizures when administered at doses of 0.1 to 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously. An effect upon seizure activity can be seen as early as 10 to 20 seconds after administration, and cerebrospinal fluid (CSF) concentrations reach half of their maximum value in three minutes. However, because of subsequent redistribution of the drug into adipose tissue, the duration of diazepam's acute anticonvulsant effect is typically &lt;20 minutes. Initial termination of seizure activity with intravenous diazepam is seen in 50 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/47\">",
"     47",
"    </a>",
"    ], but if no other medication is provided, there is a 50 percent chance of seizure recurrence within the next two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonetheless,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    remains the drug of first choice in many settings because it is stable in liquid form for long periods at room temperature. Therefore, diazepam is available in resuscitation kits in premixed form, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    are not. A rectal gel formulation of diazepam is also marketed and provides rapid delivery when intravenous access is problematic, or for at home use in patients who have frequent repetitive or prolonged seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Lorazepam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    is as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    in terminating seizures, the time from its injection to its maximum effect against seizures is as long as two minutes. The clinical advantage of lorazepam is that the effective duration of action against seizures is as long as four to six hours because of its less pronounced redistribution into adipose tissue.",
"   </p>",
"   <p>",
"    One study randomized 570 patients with a verified diagnosis of status epilepticus to one of four initial regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    (18",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    (0.15",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    plus phenytoin (18",
"    <span class=\"nowrap\">",
"     mg/kg),",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/kg).",
"    </span>",
"    In the subgroup of 384 patients with overt generalized convulsive status epilepticus, treatment with lorazepam alone was most effective in terminating seizures within 20 minutes and maintaining a seizure-free state in the first 60 minutes after treatment (65 percent versus 58 percent with phenobarbital, 56 percent with diazepam plus phenytoin, and 44 percent with phenytoin alone). This observation is supported by a Cochrane review of 11 studies encompassing 2017 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/51\">",
"     51",
"    </a>",
"    ]. No significant differences in the success rates of the different regimens were observed in the 134 patients with subtle generalized convulsive status epilepticus, and overall there were no significant differences in seizure recurrence during the 12-hour study period, outcome at 30 days, or in the incidence of adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Midazolam",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    is very effective in acutely terminating seizures (frequently in less than one minute), but it has a short half-life in the central nervous system. The advantage of midazolam over the other two benzodiazepines is that its use as a continuous infusion for refractory status epilepticus has been more thoroughly investigated and is associated with minimal cardiovascular side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/46\">",
"     46",
"    </a>",
"    ]. Effective initial intravenous doses of midazolam are a 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    bolus, followed by continuous infusion at rates of 0.75 to 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute. Some use higher doses.",
"   </p>",
"   <p>",
"    A continuous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    infusion may be less effective than high dose barbiturates or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    for the treatment of refractory status epilepticus, although high quality studies directly comparing these treatments have not been performed. Intramuscular, nasal, and buccal administration of midazolam may be useful in the rapid termination of seizures when IV access is difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a clinical trial, 893 patients were randomized to receive 10mg IM",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    or 4mg IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    in the pre-hospital treatment of status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/55\">",
"     55",
"    </a>",
"    ]. On arrival to hospital, patients receiving IM midazolam had a higher rate of seizure control (73 percent vs 63 percent) than patients receiving IV lorazepam. In this pre-hospital study, part of the superiority of the IM administration arose from the difficulty and time required to insert an IV; the treatment response for IV lorazepam was faster than IM midazolam (1.6 versus 3.3 minutes) if counted from the time of medication administration, while time to treatment administration was shorter for midazolam compared to lorazepam-treated patients (1.2 versus 4.8 minutes). Adverse reactions were similar for both treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Clobazam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/49/40727?source=see_link\">",
"     Clobazam",
"    </a>",
"    has been used to treat status epilepticus outside the United States in settings where intravenous formulations are available. It has effects similar to those of other benzodiazepines, with a rapidity of onset that is intermediate between that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    and that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    . Its duration of activity is more prolonged than that of diazepam.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Phenytoin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     Phenytoin",
"    </a>",
"    is one of the most commonly used treatments for status epilepticus, despite the trial described above which showed that initial treatment of generalized convulsive status epilepticus with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    alone was more effective than treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    and phenytoin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/47\">",
"     47",
"    </a>",
"    ]. The principal advantage of phenytoin derives from its efficacy in preventing the recurrence of status epilepticus for extended periods of time.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     Phenytoin",
"    </a>",
"    is generally infused at a rate of up to 50",
"    <span class=\"nowrap\">",
"     mg/minute",
"    </span>",
"    to a total dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    but it is critical to modify the infusion rate in the presence of hypotension or other adverse cardiovascular events. The risks of hypotension and cardiac arrhythmias increase with higher infusion rates, partly due to the propylene glycol used to solubilize phenytoin. In addition, the risks of local pain and injury (including venous thrombosis and the purple glove syndrome) increase with more rapid rates of infusion. Cardiac monitoring during the initial infusion is mandatory because bradyarrhythmias or tachyarrhythmias may occur.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     Phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    are reported to intensify seizures caused by cocaine, other local anesthetics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/34/37412?source=see_link\">",
"     lindane",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Fosphenytoin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"     Fosphenytoin",
"    </a>",
"    is a pro-drug of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    that is hydrolyzed into phenytoin by serum phosphatases. Fosphenytoin is highly water soluble and therefore unlikely to precipitate during intravenous administration. The risk of local irritation at the site of infusion is significantly reduced compared with phenytoin; fosphenytoin can therefore be infused much more rapidly (up to 150",
"    <span class=\"nowrap\">",
"     mg/minute",
"    </span>",
"    versus 50",
"    <span class=\"nowrap\">",
"     mg/minute",
"    </span>",
"    with phenytoin). In addition, the increased water solubility of fosphenytoin makes intramuscular (IM) administration possible if intravenous (IV) access cannot be obtained. However, IM administration will yield less predictable levels and a longer time to onset of effect than IV administration.",
"   </p>",
"   <p>",
"    Because propylene glycol is not required to solubilize",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    , the cardiovascular side effects of fosphenytoin may be less frequent and severe than those of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    . However, at least two studies have suggested that the incidence of adverse hemodynamic effects with fosphenytoin and phenytoin infusions is similar [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    is converted on a 1:1 molar basis to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , the dosing of fosphenytoin in terms of moles is identical. However, the molecular weight of fosphenytoin is greater than that of phenytoin; hence, a greater weight of fosphenytoin must be given in order to yield the same concentration of phenytoin. To eliminate this problem, the manufacturer recommends prescribing of fosphenytoin as milligrams of phenytoin equivalent (PE). Orders for fosphenytoin should be written in terms of PEs; as an example, 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    PE load at a rate of 100 to 150 mg",
"    <span class=\"nowrap\">",
"     PE/minute.",
"    </span>",
"    Cardiac monitoring and frequent vital signs are",
"    <strong>",
"     required",
"    </strong>",
"    during the infusion of fosphenytoin or phenytoin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Barbiturates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Barbiturates are similar to benzodiazepines in that they also bind to the GABA(A) receptor, amplifying the actions of GABA by extending GABA-mediated chloride channel openings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/61\">",
"     61",
"    </a>",
"    ]. This process permits an increasing flow of chloride ions across the membrane, causing neuronal hyperpolarization (eg, membrane inhibition to depolarization).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"     pentobarbital",
"    </a>",
"    are the most useful barbiturates in the treatment of status epilepticus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Phenobarbital",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     Phenobarbital",
"    </a>",
"    is an excellent anticonvulsant, especially in the acute management of seizures. Various studies have shown a rate of seizure control of approximately 60 percent when phenobarbital is used alone; this rate is similar to that seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    alone or the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/47,62\">",
"     47,62",
"    </a>",
"    ]. Despite its efficacy, phenobarbital is generally not used as a first-line treatment in adults because, administration is slow, it causes prolonged sedation, and it is believed to carry a higher risk of hypoventilation and hypotension than benzodiazepines or phenytoin.",
"   </p>",
"   <p>",
"    Initial doses of 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    infused at a rate of 30 to 50",
"    <span class=\"nowrap\">",
"     mg/minute",
"    </span>",
"    are generally used, but slower infusion rates should be used in the elderly. Careful monitoring of respiratory and cardiac status is mandatory. It is often necessary to intubate patients in order to provide a secure airway and minimize the risk of aspiration if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    is administered following benzodiazepines. The risk of prolonged sedation with phenobarbital is greater than with the other anticonvulsants because of its half-life of 87 to 100 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Pentobarbital",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"     Pentobarbital",
"    </a>",
"    is used primarily in the treatment of refractory status epilepticus, typically with a loading dose of 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    infused at a rate of up to 100",
"    <span class=\"nowrap\">",
"     mg/minute",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/63\">",
"     63",
"    </a>",
"    ]. After the loading dose is administered, it is often necessary to use a continuous infusion of pentobarbital ranging from 1 to 4",
"    <span class=\"nowrap\">",
"     mg/kg/hour",
"    </span>",
"    in order to maintain the patient in a seizure-free state. The ultimate infusion rate is determined by the amount of drug required to terminate status epilepticus, but can be limited by hypotension due to the drug's adverse inotropic and vasodilatory effects. Vasopressors are almost universally required during high dose pentobarbital infusions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Thiopental",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some centers use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    instead of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"     pentobarbital",
"    </a>",
"    for refractory status epilepticus, but there are a number of problems with this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/44\">",
"     44",
"    </a>",
"    ]. Animal studies suggest that thiopental carries a higher incidence of adverse cardiovascular effects than pentobarbital. The half-life of thiopental is shorter than that of pentobarbital, but this is counterbalanced by the fact that thiopental is degraded to active metabolites (including pentobarbital), which accumulate with longer term infusions. Thiopental may also have immunosuppressive effects on neutrophil function and mucociliary clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An uncontrolled series of 10 consecutive adults presenting with status epilepticus noted that high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"     thiopental",
"    </a>",
"    therapy effectively terminated clinical and electrophysiological evidence of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/66\">",
"     66",
"    </a>",
"    ]. However, therapy was associated with systemic hypotension; each patient required fluid resuscitation with an average of 2.6 L of crystalloid in the first 24 hours. High-dose thiopental resulted in delayed recovery from anesthesia, and six patients developed S. aureus pneumonia, resulting in prolonged intubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Propofol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    is a hindered phenolic compound with anticonvulsant properties. The drug is unrelated to any of the currently used barbiturate, opioid, benzodiazepine, arylcyclohexylamine, or imidazole intravenous anesthetic agents. Hypotension and respiratory depression may complicate its use.",
"   </p>",
"   <p>",
"    Experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    in the treatment of status epilepticus is limited, but promising results have been reported in several small trials [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/18,27,67\">",
"     18,27,67",
"    </a>",
"    ]. As an example, one study compared the results of treatment with propofol or high dose barbiturates in 16 patients with refractory status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/68\">",
"     68",
"    </a>",
"    ]. Termination of seizures was significantly faster among successfully treated patients in the propofol group (mean 3 versus 123 minutes), but there was a nonsignificant trend toward higher overall success rates in barbiturate-treated patients (82 versus 63 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     Propofol",
"    </a>",
"    is associated with rare but serious, potentially fatal adverse effects including a syndrome of metabolic acidosis, rhabdomyolysis, renal failure, and cardiac dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/69\">",
"     69",
"    </a>",
"    ]. This may be mitigated by avoiding high doses for more than two days and laboratory monitoring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link&amp;anchor=H7#H7\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\", section on 'Available agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Valproic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of intravenous (IV) valproic acid (Depacon) is increasingly used in the treatment of status epilepticus. (FDA) approved it only for slow infusion rates (up to 20",
"    <span class=\"nowrap\">",
"     mg/min).",
"    </span>",
"    &nbsp;Accumulating evidence suggests that IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    can be safely infused at rates up to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute in adults without adverse effects on blood pressure or heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/70-74\">",
"     70-74",
"    </a>",
"    ]. Rapid IV loading may be desirable as a way to achieve serum concentrations &gt;100",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    quickly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H19#H19\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Valproate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The limited available data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    may be useful in treating acute status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/73,75-77\">",
"     73,75-77",
"    </a>",
"    ]. As an example, an unblinded, randomized trial in 68 patients with convulsive status epilepticus suggested that high-dose valproate infusions (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over 15 minutes) terminated seizures more quickly than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    infusions (18",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at 50",
"    <span class=\"nowrap\">",
"     mg/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/77\">",
"     77",
"    </a>",
"    ]. In another randomized study, valproate and phenytoin infusions were similarly effective, but valproate was better tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/78\">",
"     78",
"    </a>",
"    ]. The risk of hyperammonemic encephalopathy due to valproate may pose diagnostic challenges in the postictal setting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28264?source=see_link\">",
"     \"Valproic acid poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Newer AEDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;While preliminary evidence is promising, further study is needed before newer AEDs have a defined role in the treatment of status epilepticus.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    is a broad spectrum antiepileptic drug. Topiramate, administered via nasogastric tube, may have some efficacy in refractory status epilepticus as reported in some case reports and small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. Further prospective study is needed to define a role for topiramate in the treatment of status epilepticus. Its use is not recommended at this time.",
"   </p>",
"   <p>",
"    Case series of 18 to 43 patients with status epilepticus refractory to benzodiazepines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other AEDs who were treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    suggests that this is a safe and effective treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. &nbsp;However, the efficacy of levetiracetam relative to other agents has yet to be studied in prospective controlled studies. In one retrospective (not randomized) study, levetiracetam was associated with a higher rate of failure to control seizures compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    (48 versus 25 percent) when used as a second-line treatment for status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one case series of 48 patients, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/19/35125?source=see_link\">",
"     lacosamide",
"    </a>",
"    (200 to 400 mg IV) appeared to be affective in the treatment of status epilepticus and seizure clusters when used either as a first-line treatment or for refractory status epilepticus [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient with possible status epilepticus requires rapid evaluation and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/88\">",
"     88",
"    </a>",
"    ]. There are many possible pharmacologic approaches to status epilepticus; successful approaches to management have been developed empirically, since there are few controlled trials comparing different regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Although there are differences in efficacy and side effect profile among effective agents, it is important to become familiar with and primarily use one reasonable treatment method.",
"   </p>",
"   <p>",
"    We divide the initial management into three phases:",
"    <span class=\"nowrap\">",
"     assessment/supportive",
"    </span>",
"    treatment, initial pharmacologic therapy, and secondary pharmacotherapy (if required) for the treatment of refractory seizures (",
"    <a class=\"graphic graphic_algorithm graphicRef74649 \" href=\"UTD.htm?9/16/9475\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Assessment and support",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid neurologic examination should be performed to provide a preliminary classification of the type of status epilepticus and its probable etiology. The patient should also undergo a rapid general evaluation, with particular attention to respiratory and circulatory status, and supportive therapy (eg, oxygen, mechanical ventilation) should be instituted as needed.",
"   </p>",
"   <p>",
"    During this time, intravenous catheters should be placed and blood obtained for electrolyte, serum glucose, and toxicology studies, a complete blood count, and a rapid \"finger-stick\" glucose. Measurement of arterial blood gases is often valuable and may suggest a need for intubation and mechanical ventilatory support. Cardiac monitoring, frequent measurement of blood pressure, and pulse oximetry should be instituted. These tasks may require one to five minutes and may overlap with the next phase of treatment (",
"    <a class=\"graphic graphic_algorithm graphicRef74649 \" href=\"UTD.htm?9/16/9475\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Initial pharmacologic therapy for patients in an ER or hospital setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    0.02 to 0.03",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    should be administered intravenously and approximately one minute allowed to assess its effect.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     Diazepam",
"    </a>",
"    0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV may be substituted if lorazepam is not available. If IV access is not available, midazolam 10mg IM for patients with a body weight &gt;40kg and 5mg IM for patients with a body weight of 13 to 40kg is an alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If seizures continue at this point, additional doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    (up to a cumulative dose of 0.1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    should be infused at a maximum rate of 2",
"    <span class=\"nowrap\">",
"     mg/minute,",
"    </span>",
"    and a second intravenous catheter placed in order to begin a concomitant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    ) loading infusion. Even if seizures terminate after the initial lorazepam dose, therapy with phenytoin or fosphenytoin is generally indicated to prevent the recurrence of seizures.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     Phenytoin",
"    </a>",
"    (but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    ) and any of the benzodiazepines are incompatible and will precipitate if infused through the same intravenous line. A phenytoin infusion of 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (or 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    phenytoin equivalents (PE) for fosphenytoin) should be started at 25 to 50",
"    <span class=\"nowrap\">",
"     mg/min",
"    </span>",
"    (or 100 mg",
"    <span class=\"nowrap\">",
"     PE/minute",
"    </span>",
"    for fosphenytoin) and reduced if significant adverse effects of the infusion are seen. This phase of treatment usually lasts approximately 30 minutes (",
"    <a class=\"graphic graphic_algorithm graphicRef74649 \" href=\"UTD.htm?9/16/9475\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Treatment of refractory seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Status epilepticus that is refractory to first line anticonvulsants indicates a grave prognosis and requires management in an intensive care setting. After failure of the first line therapy discussed above, the next step is to consider infusion of another 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    (or 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    PE of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    ) and up to another 0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    if the patient is stable. Metabolic derangements from initial laboratory studies should be appropriately treated.",
"   </p>",
"   <p>",
"    Further measures are required if seizures continue, but whereas there is reasonable agreement upon treatment up to this point, the optimal therapy of refractory status epilepticus is less well defined. Regardless of the specifics of pharmacologic therapy, it is critical to provide adequate ventilatory and hemodynamic support. Patients with refractory seizures should be endotracheally intubated, and continuous electroencephalogram (EEG) recordings are desirable [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary drugs used for refractory status epilepticus are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"     pentobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    . There is no consensus about which should be used first. A systematic review of drug therapy for refractory status epilepticus assessed data on 193 patients from 28 trials in an attempt to clarify this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/89\">",
"     89",
"    </a>",
"    ]. Overall mortality was 48 percent, but there was no association between drug selection and the risk of death. Pentobarbital was more effective than either propofol or midazolam in preventing breakthrough seizures (12 versus 42 percent), but was associated with a significantly increased incidence of hypotension, defined as a systolic blood pressure below 100 mmHg (77 versus 34 percent). Another study of 107 patients failed to show an influence of the therapy used on the outcome of refractory status [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further pharmacologic therapy at this point is based primarily upon the patient's hemodynamic stability and the risk for prolonged mechanical ventilation (",
"    <a class=\"graphic graphic_algorithm graphicRef74649 \" href=\"UTD.htm?9/16/9475\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Hemodynamically stable patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with high-dose barbiturates (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"     pentobarbital",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ) remains common in this setting because of the greatest experience with its use [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/63\">",
"     63",
"    </a>",
"    ]. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    is gaining some acceptance in this setting for patients who are already intubated because response to therapy is very rapid, allowing a rapid change to another regimen if propofol infusion is unsuccessful. Continuous EEG monitoring should be instituted, if possible, along with continuous pulse oximetry and blood pressure monitoring via an arterial catheter. Vasopressors should be available at the bedside. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An initial dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    should be infused at a maximum rate of 100",
"    <span class=\"nowrap\">",
"     mg/minute.",
"    </span>",
"    If seizure activity continues, a dose of 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"     pentobarbital",
"    </a>",
"    should be infused while careful attention is paid to the EEG and hemodynamic status. Additional doses of pentobarbital at rates up to 100",
"    <span class=\"nowrap\">",
"     mg/min",
"    </span>",
"    should be infused until all seizures stop.",
"   </p>",
"   <p>",
"    Subclinical seizures may still be evident on the EEG after clinical seizures have stopped. As it is important to stop both clinical and electrographic seizures, EEG monitoring is important in the treatment of refractory status epilepticus. However, it can be difficult to be certain if electrographic patterns are ictal or interictal. Thus, it is common practice to titrate therapy until the EEG shows a pattern that is clearly not ictal. A burst suppression pattern is often chosen as an electrographic endpoint because it is clearly not ictal and is easy to recognize [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Almost all patients at this point will require vasopressor support (typically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    or dopamine), as well as crystalloid infusions. The mortality rate associated with barbiturate coma is high because of adverse hemodynamic effects and the severity of the underlying neurologic process, and reaches 80 percent in patients over 70.",
"   </p>",
"   <p>",
"    If seizures are terminated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"     pentobarbital",
"    </a>",
"    , then an infusion at 1 to 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour should be maintained for 24 hours and tapered over the following 24 hours. Some physicians may prolong the duration of high-dose therapy if frequent focal epileptiform discharges remain on the EEG after treatment. During this time, high therapeutic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    concentrations must be maintained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Hemodynamically unstable patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with barbiturates or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    may significantly worsen the hemodynamics of unstable patients. Therefore, one option is to proceed with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    infusion because it is the best-tolerated treatment in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/3,46\">",
"     3,46",
"    </a>",
"    ]. Generally, therapy is initiated with a 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    bolus, followed by a continuous infusion of 0.05 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour. If this is unsuccessful within 45 to 60 minutes, a propofol or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/31/4601?source=see_link\">",
"     pentobarbital",
"    </a>",
"    infusion should be started.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Patients at high risk for respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are at high risk for prolonged mechanical ventilation (eg, those with severe COPD, severe debilitation, or cancer) should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    in an attempt to minimize the duration of sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/68\">",
"     68",
"    </a>",
"    ]. Pressors should be ready at the bedside, and blood pressure and EEG should be monitored closely while propofol infusion is initiated at 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour. This infusion should be titrated over the next 20 to 60 minutes to maintain a seizure-free state and burst suppression on the EEG. Infusion rates up to 10 to 12",
"    <span class=\"nowrap\">",
"     mg/kg/hour",
"    </span>",
"    may be required, but should not be maintained for more than 18 to 48 hours because of the risk of the propofol infusion syndrome. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Propofol'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If seizures are controlled with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    , the effective infusion rate should be maintained for 24 hours and then tapered at a rate of 5 percent per hour. This prevents rebound seizures that commonly occur with abrupt propofol discontinuation. It is critical that high therapeutic levels of at least one anticonvulsant (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    levels &gt;25",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [99",
"    <span class=\"nowrap\">",
"     &micro;mol/L]",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    levels &gt;30",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    [129",
"    <span class=\"nowrap\">",
"     &micro;mol/L])",
"    </span>",
"    are obtained prior to tapering the propofol in order to reduce the risk of seizure recurrence.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    should generally be considered unsuccessful if it does not terminate seizure activity within 45 to 60 minutes. In this case, a high dose barbiturate infusion should be considered. Propofol infusions for refractory status epilepticus are relatively new in comparison with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    or high dose barbiturates. However, as clinical experience with propofol sedation in the intensive care setting grows, this agent is increasingly used in patients with refractory status persisting after intubation. It remains critical that propofol be employed cautiously and by individuals familiar with its use in this context. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Propofol'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Malignant status epilepticus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"malignant\" status epilepticus has been introduced to refer to status epilepticus that either fails to respond to the therapies discussed above or recurs quickly on tapering these medications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/91\">",
"     91",
"    </a>",
"    ]. It has been reported that as many as 20 percent of patients with refractory status epilepticus evolve into malignant status epilepticus, a transition that is associated with a very poor prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Out-of-hospital/prehospital treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of status epilepticus out of hospital by paramedics appears to be safe and effective. In a randomized, double-blind study of 205 patients with status epilepticus, of whom 66 received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    , 68 received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    , and 71 received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/92\">",
"     92",
"    </a>",
"    ]. Status epilepticus had been terminated on arrival to the emergency department in more patients treated with lorazepam and diazepam than placebo (59, 43, and 21 percent, respectively). Active treatment also reduced the rates of respiratory or circulatory complications (10.6, 10.3, and 22.5 percent, respectively).",
"   </p>",
"   <p>",
"    In another randomized study in the prehospital setting, 10 IM",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    was as least as effective as 4mg IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    in adults, particularly if intravenous access is not immediately accessible [",
"    <a class=\"abstract\" href=\"UTD.htm?19/11/19642/abstract/55\">",
"     55",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/40/43650?source=see_link\">",
"       \"Patient information: Epilepsy in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Status epilepticus refers to the occurrence of a single unremitting seizure with a duration longer than 5 to 10 minutes or frequent clinical seizures without an interictal return to the baseline clinical state.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Etiologies include noncompliance with antiepileptic drug (AED) treatment, drug or alcohol withdrawal syndromes, acute brain injury or infection, and metabolic disturbances, among others. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis depends most strongly on the underlying etiology; however, there is some evidence that status epilepticus is independently associated with mortality and neurologic sequelae. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Complications and outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of status epilepticus can be difficult. A careful neurologic examination is critical. Electroencephalogram (EEG) studies are especially important in situations where there is a high risk of nonconvulsive status epilepticus or there is any uncertainty in the correct diagnosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial assessment and treatment of a patient in status epilepticus should proceed relatively simultaneously. Hemodynamic and respiratory monitoring are also required in order to avoid side effects of therapy (",
"      <a class=\"graphic graphic_algorithm graphicRef74649 \" href=\"UTD.htm?9/16/9475\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Assessment and support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      0.02 to 0.03",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV as the initial treatment for status epilepticus (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This should be repeated, as needed up to 0.1",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      A loading dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/51/14138?source=see_link\">",
"       fosphenytoin",
"      </a>",
"      should follow in order to maintain anti-seizure effect (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Initial pharmacologic therapy for patients in an ER or hospital setting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many possible approaches to the treatment of status epilepticus. One possible approach is summarized in the accompanying protocol (",
"      <a class=\"graphic graphic_algorithm graphicRef74649 \" href=\"UTD.htm?9/16/9475\">",
"       algorithm 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Treatment of refractory seizures'",
"      </a>",
"      above.) Clinicians should employ those medication regimens with which they and the care team are familiar in order to avoid unintended complications of therapy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/1\">",
"      Aminoff MJ, Simon RP. Status epilepticus. Causes, clinical features and consequences in 98 patients. Am J Med 1980; 69:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/2\">",
"      Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus. JAMA 1993; 270:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/3\">",
"      Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med 1998; 338:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/4\">",
"      DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol 1995; 12:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/5\">",
"      Mayer SA, Claassen J, Lokin J, et al. Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 2002; 59:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/6\">",
"      Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 2005; 76:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/7\">",
"      Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia 1994; 35:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/8\">",
"      Boyd JG, Taylor S, Rossiter JP, et al. New-onset refractory status epilepticus with restricted DWI and neuronophagia in the pulvinar. Neurology 2010; 74:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/9\">",
"      Wilder-Smith EP, Lim EC, Teoh HL, et al. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singapore 2005; 34:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/10\">",
"      Costello DJ, Kilbride RD, Cole AJ. Cryptogenic New Onset Refractory Status Epilepticus (NORSE) in adults-Infectious or not? J Neurol Sci 2009; 277:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/11\">",
"      Rathakrishnan R, Wilder-Smith EP. New onset refractory status epilepticus (NORSE). J Neurol Sci 2009; 284:220; author reply 220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/12\">",
"      Bausell R, Svoronos A, Lennihan L, Hirsch LJ. Recovery after severe refractory status epilepticus and 4 months of coma. Neurology 2011; 77:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/13\">",
"      Logroscino G, Hesdorffer DC, Cascino G, et al. Short-term mortality after a first episode of status epilepticus. Epilepsia 1997; 38:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/14\">",
"      Hauser WA. Status epilepticus: epidemiologic considerations. Neurology 1990; 40:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/15\">",
"      Chin RF, Neville BG, Scott RC. A systematic review of the epidemiology of status epilepticus. Eur J Neurol 2004; 11:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/16\">",
"      Koubeissi M, Alshekhlee A. In-hospital mortality of generalized convulsive status epilepticus: a large US sample. Neurology 2007; 69:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/17\">",
"      Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology 1993; 43:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/18\">",
"      Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia 2001; 42:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/19\">",
"      Rossetti AO, Hurwitz S, Logroscino G, Bromfield EB. Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry 2006; 77:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/20\">",
"      Canou&iuml;-Poitrine F, Bastuji-Garin S, Alonso E, et al. Risk and prognostic factors of status epilepticus in the elderly: a case-control study. Epilepsia 2011; 52:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/21\">",
"      Alvarez V, Januel JM, Burnand B, Rossetti AO. Role of comorbidities in outcome prediction after status epilepticus. Epilepsia 2012; 53:e89.",
"     </a>",
"    </li>",
"    <li>",
"     Shorvon S. Prognosis and outcome of status epilepticus. In: Status epilepticus: its clinical features and treatment in children and adults, Shorvon S.  (Ed), Cambridge University Press, Cambridge 1999. p.293.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/23\">",
"      Claassen J, Lokin JK, Fitzsimmons BF, et al. Predictors of functional disability and mortality after status epilepticus. Neurology 2002; 58:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/24\">",
"      Manno EM, Pfeifer EA, Cascino GD, et al. Cardiac pathology in status epilepticus. Ann Neurol 2005; 58:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/25\">",
"      Simon RP, Aminoff MJ, Benowitz NL. Changes in plasma catecholamines after tonic-clonic seizures. Neurology 1984; 34:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/26\">",
"      Fountain NB, Lothman EW. Pathophysiology of status epilepticus. J Clin Neurophysiol 1995; 12:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/27\">",
"      Payne TA, Bleck TP. Status epilepticus. Crit Care Clin 1997; 13:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/28\">",
"      Chapman MG, Smith M, Hirsch NP. Status epilepticus. Anaesthesia 2001; 56:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/29\">",
"      Donaire A, Carreno M, G&oacute;mez B, et al. Cortical laminar necrosis related to prolonged focal status epilepticus. J Neurol Neurosurg Psychiatry 2006; 77:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/30\">",
"      Parmar H, Lim SH, Tan NC, Lim CC. Acute symptomatic seizures and hippocampus damage: DWI and MRS findings. Neurology 2006; 66:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/31\">",
"      Scholtes FB, Renier WO, Meinardi H. Generalized convulsive status epilepticus: causes, therapy, and outcome in 346 patients. Epilepsia 1994; 35:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/32\">",
"      Cooper AD, Britton JW, Rabinstein AA. Functional and cognitive outcome in prolonged refractory status epilepticus. Arch Neurol 2009; 66:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/33\">",
"      Legriel S, Azoulay E, Resche-Rigon M, et al. Functional outcome after convulsive status epilepticus. Crit Care Med 2010; 38:2295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/34\">",
"      Hesdorffer DC, Logroscino G, Cascino GD, Hauser WA. Recurrence of afebrile status epilepticus in a population-based study in Rochester, Minnesota. Neurology 2007; 69:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/35\">",
"      Westmoreland BF. Epileptiform electroencephalographic patterns. Mayo Clin Proc 1996; 71:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/36\">",
"      Reiher J, Rivest J, Grand'Maison F, Leduc CP. Periodic lateralized epileptiform discharges with transitional rhythmic discharges: association with seizures. Electroencephalogr Clin Neurophysiol 1991; 78:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/37\">",
"      Tatum WO, Alavi A, Stecker MM. Technetium-99m-HMPAO SPECT in partial status epilepticus. J Nucl Med 1994; 35:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/38\">",
"      Henry TR, Drury I, Brunberg JA, et al. Focal cerebral magnetic resonance changes associated with partial status epilepticus. Epilepsia 1994; 35:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/39\">",
"      Chu K, Kang DW, Kim JY, et al. Diffusion-weighted magnetic resonance imaging in nonconvulsive status epilepticus. Arch Neurol 2001; 58:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/40\">",
"      Briellmann RS, Wellard RM, Jackson GD. Seizure-associated abnormalities in epilepsy: evidence from MR imaging. Epilepsia 2005; 46:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/41\">",
"      Privitera M, Hoffman M, Moore JL, Jester D. EEG detection of nontonic-clonic status epilepticus in patients with altered consciousness. Epilepsy Res 1994; 18:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/42\">",
"      Chen DK, So YT, Fisher RS, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2005; 65:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/43\">",
"      Holtkamp M, Othman J, Buchheim K, Meierkord H. Diagnosis of psychogenic nonepileptic status epilepticus in the emergency setting. Neurology 2006; 66:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/44\">",
"      Walker MC, Smith SJ, Shorvon SD. The intensive care treatment of convulsive status epilepticus in the UK. Results of a national survey and recommendations. Anaesthesia 1995; 50:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/45\">",
"      Treiman DM. Pharmacokinetics and clinical use of benzodiazepines in the management of status epilepticus. Epilepsia 1989; 30 Suppl 2:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/46\">",
"      Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. Crit Care Med 1992; 20:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/47\">",
"      Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/48\">",
"      Prensky AL, Raff MC, Moore MJ, Schwab RS. Intravenous diazepam in the treatment of prolonged seizure activity. N Engl J Med 1967; 276:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/49\">",
"      Walker M. Status epilepticus: an evidence based guide. BMJ 2005; 331:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/50\">",
"      Fakhoury T, Chumley A, Bensalem-Owen M. Effectiveness of diazepam rectal gel in adults with acute repetitive seizures and prolonged seizures: a single-center experience. Epilepsy Behav 2007; 11:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/51\">",
"      Prasad K, Al-Roomi K, Krishnan PR, Sequeira R. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev 2005; :CD003723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/52\">",
"      Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav 2004; 5:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/53\">",
"      McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet 2005; 366:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/54\">",
"      de Haan GJ, van der Geest P, Doelman G, et al. A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations. Epilepsia 2010; 51:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/55\">",
"      Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012; 366:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/56\">",
"      Wills B, Erickson T. Chemically induced seizures. Clin Lab Med 2006; 26:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/57\">",
"      Paloucek FP, Rodvold KA. Evaluation of theophylline overdoses and toxicities. Ann Emerg Med 1988; 17:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/58\">",
"      Blake KV, Massey KL, Hendeles L, et al. Relative efficacy of phenytoin and phenobarbital for the prevention of theophylline-induced seizures in mice. Ann Emerg Med 1988; 17:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/59\">",
"      Coplin WM, Rhoney DH, Rebuck JA, et al. Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. Neurol Res 2002; 24:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/60\">",
"      Swadron SP, Rudis MI, Azimian K, et al. A comparison of phenytoin-loading techniques in the emergency department. Acad Emerg Med 2004; 11:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/61\">",
"      Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989; 25:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/62\">",
"      Shaner DM, McCurdy SA, Herring MO, Gabor AJ. Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology 1988; 38:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/63\">",
"      Yaffe K, Lowenstein DH. Prognostic factors of pentobarbital therapy for refractory generalized status epilepticus. Neurology 1993; 43:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/64\">",
"      Kress HG, Segm&uuml;ller R. [Intravenous anesthetics and human neutrophil granulocyte motility in vitro]. Anaesthesist 1987; 36:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/65\">",
"      Forbes AR, Gamsu G. Depression of lung mucociliary dlearance by thiopental and halothane. Anesth Analg 1979; 58:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/66\">",
"      Parviainen I, Uusaro A, K&auml;lvi&auml;inen R, et al. High-dose thiopental in the treatment of refractory status epilepticus in intensive care unit. Neurology 2002; 59:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/67\">",
"      Rossetti AO, Reichhart MD, Schaller MD, et al. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 2004; 45:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/68\">",
"      Stecker MM, Kramer TH, Raps EC, et al. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia 1998; 39:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/69\">",
"      Zarovnaya EL, Jobst BC, Harris BT. Propofol-associated fatal myocardial failure and rhabdomyolysis in an adult with status epilepticus. Epilepsia 2007; 48:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/70\">",
"      Sinha S, Naritoku DK. Intravenous valproate is well tolerated in unstable patients with status epilepticus. Neurology 2000; 55:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/71\">",
"      Ramsay RE, Cantrell D, Collins SD, et al. Safety and tolerance of rapidly infused Depacon. A randomized trial in subjects with epilepsy. Epilepsy Res 2003; 52:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/72\">",
"      Wheless JW, Vazquez BR, Kanner AM, et al. Rapid infusion with valproate sodium is well tolerated in patients with epilepsy. Neurology 2004; 63:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/73\">",
"      Limdi NA, Shimpi AV, Faught E, et al. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005; 64:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/74\">",
"      Limdi NA, Knowlton RK, Cofield SS, et al. Safety of rapid intravenous loading of valproate. Epilepsia 2007; 48:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/75\">",
"      Hodges BM, Mazur JE. Intravenous valproate in status epilepticus. Ann Pharmacother 2001; 35:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/76\">",
"      Yu KT, Mills S, Thompson N, Cunanan C. Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. Epilepsia 2003; 44:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/77\">",
"      Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 2006; 67:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/78\">",
"      Agarwal P, Kumar N, Chandra R, et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 2007; 16:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/79\">",
"      Rossetti AO, Bromfield EB. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurology 2005; 65:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/80\">",
"      Towne AR, Garnett LK, Waterhouse EJ, et al. The use of topiramate in refractory status epilepticus. Neurology 2003; 60:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/81\">",
"      Bensalem MK, Fakhoury TA. Topiramate and status epilepticus: report of three cases. Epilepsy Behav 2003; 4:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/82\">",
"      Reuber M, Evans J, Bamford JM. Topiramate in drug-resistant complex partial status epilepticus. Eur J Neurol 2002; 9:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/83\">",
"      Knake S, Gruener J, Hattemer K, et al. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry 2008; 79:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/84\">",
"      M&ouml;ddel G, Bunten S, Dobis C, et al. Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus. J Neurol Neurosurg Psychiatry 2009; 80:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/85\">",
"      Eue S, Grumbt M, M&uuml;ller M, Schulze A. Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. Epilepsy Behav 2009; 15:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/86\">",
"      Alvarez V, Januel JM, Burnand B, Rossetti AO. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia 2011; 52:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/87\">",
"      H&ouml;fler J, Unterberger I, Dobesberger J, et al. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia 2011; 52:e148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/88\">",
"      Marik PE, Varon J. The management of status epilepticus. Chest 2004; 126:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/89\">",
"      Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002; 43:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/90\">",
"      Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 2005; 62:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/91\">",
"      Holtkamp M, Othman J, Buchheim K, et al. A \"malignant\" variant of status epilepticus. Arch Neurol 2005; 62:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/11/19642/abstract/92\">",
"      Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001; 345:631.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2217 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19642=[""].join("\n");
var outline_f19_11_19642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      COMPLICATIONS AND OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Electroencephalogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Single photon emission computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Simple partial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Complex partial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Generalized tonic-clonic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Less common varieties",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Absence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Myoclonic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Psychogenic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PHARMACOLOGIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Diazepam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Lorazepam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Midazolam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Clobazam",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Phenytoin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Fosphenytoin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Barbiturates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Phenobarbital",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Pentobarbital",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Thiopental",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Propofol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Valproic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Newer AEDs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Assessment and support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Initial pharmacologic therapy for patients in an ER or hospital setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Treatment of refractory seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Hemodynamically stable patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Hemodynamically unstable patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Patients at high risk for respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Malignant status epilepticus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Out-of-hospital/prehospital treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/2217\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2217|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?9/16/9475\" title=\"algorithm 1\">",
"      Treatment of status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2217|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?14/26/14761\" title=\"waveform 1\">",
"      EEG periodic lateralized epileptiform discharges PLEDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26952?source=related_link\">",
"      Cardiac complications of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=related_link\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/40/43650?source=related_link\">",
"      Patient information: Epilepsy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=related_link\">",
"      Psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28264?source=related_link\">",
"      Valproic acid poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_11_19643="Normal urinary values children 24-hour urine collection";
var content_f19_11_19643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal urinary values in school-aged children based on 24-hour urine collection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Solute",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal urine value in 24-hour urine collection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium",
"       </td>",
"       <td>",
"        &lt;4 mg/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxalate",
"       </td>",
"       <td>",
"        &lt;50 mg/1.73 m",
"        <sup>",
"         2",
"        </sup>",
"        per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystine",
"       </td>",
"       <td>",
"        &lt;60 mg/1.73 m",
"        <sup>",
"         2",
"        </sup>",
"        per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citrate",
"       </td>",
"       <td>",
"        &gt;400 mg/g creatinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uric acid*",
"       </td>",
"       <td>",
"        &lt;0.56 mg/dL glomerular filtration rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine volume",
"       </td>",
"       <td>",
"        &gt;20 ml/kg per day",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Uric acid/glomerular filtration rate calculated using the following equation, where UCr and PCr are the urine and plasma creatinine concentrations, respectively: Uric acid/GFR, mg/dL = Urine Uric Acid &divide; UCr x PCr.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19643=[""].join("\n");
var outline_f19_11_19643=null;
var title_f19_11_19644="Dx extrahepatic cholestasis";
var content_f19_11_19644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73409&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of cholestatic jaundice: Extrahepatic",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            \"Cholangiopathies\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cholelithiasis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Biliary strictures after invasive procedure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cholangiocellular carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Primary sclerosing cholangitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            AIDS cholangiopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            CMV",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Cryptosporidium sp",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            HIV",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Choledochal cyst",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sphincter of Oddi dysfunction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Parasitic infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Ascaris lumricoides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Histiocytosis X",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Extrinsic causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis (acute and chronic)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatic carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Portal adenopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Metastases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Periampullary carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Periampullary diverticulum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mirizzi's syndrome",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19644=[""].join("\n");
var outline_f19_11_19644=null;
var title_f19_11_19645="Drugs and doses for pharmacological conversion of AF";
var content_f19_11_19645=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs and doses for pharmacological conversion of (recent-onset) AF (European Society of Cardiology)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow-up dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Amiodarone",
"        </strong>",
"       </td>",
"       <td>",
"        5 mg/kg IV over 1 hour",
"       </td>",
"       <td>",
"        50 mg per hour",
"       </td>",
"       <td>",
"        Phlebitis, hypotension. Will slow the ventricular rate. Delayed AF conversion to sinus rhythm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Flecainide",
"        </strong>",
"       </td>",
"       <td>",
"        2 mg/kg IV over 10 minutes, or 200 to 300 mg orally",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Not suitable for patients with marked structural heart disease; may prolong QRS duration, and hence the QT interval; and may inadvertently increase the ventricular rate due to conversion to atrial flutter and 1:1 conduction to the ventricles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ibutilide",
"        </strong>",
"       </td>",
"       <td>",
"        1 mg IV over 10 minutes",
"       </td>",
"       <td>",
"        1 mg IV over 10 minutes after waiting for 10 minutes",
"       </td>",
"       <td>",
"        Can cause prolongation of the QT interval and torsades de pointes; watch for abnormal T-U waves or QT prolongation. Will slow the ventricular rate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Propafenone",
"        </strong>",
"       </td>",
"       <td>",
"        2 mg/kg IV over 10 minutes, or 450 to 600 mg orally",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Not suitable for patients with marked structural heart disease; may prolong QRS duration; will slightly slow the ventricular rate, but may inadvertently increase the ventricular rate due to conversion to atrial flutter and 1:1 conduction to the ventricles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Vernakalant",
"        </strong>",
"       </td>",
"       <td>",
"        3 mg/kg IV over 10 minutes",
"       </td>",
"       <td>",
"        Second infusion of 2 mg/kg IV over 10 minutes after 15 minute rest",
"       </td>",
"       <td>",
"        So far only evaluated in clinical trials; recently approved.*",
"        <sup>",
"         [1-3]",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Vernakalant has recently been recommended for approval by the European Medicines Agency for rapid cardioversion of recent-onset AF to sinus rhythm in adults (&ge;7 days for non-surgical patients; &ge;3 days for surgical patients).",
"     <sup>",
"      [1,2]",
"     </sup>",
"     A direct comparison with amiodarone in the AVRO trial (Phase III prospective, randomized, double-blind, active-controlled, multi-center, superiority study of Vernakalant injection versus amiodarone in subjects with recent onset atrial fibrillation), vernakalant was more effective than amiodarone for the rapid conversion of AF to sinus rhythm (51.7 percent versus 5.7 percent at 90 min after the start of treatment; p&lt;0.0001).",
"     <sup>",
"      [3]",
"     </sup>",
"     It is to be given as an initial IV infusion (3 mg/kg over 10 minutes), followed by 15 minutes of observation and a further IV infusion (2 mg/kg over 10 minutes), if necessary. Vernakalant is contraindicated in patients with systolic blood pressure &lt;100 mmHg, severe aortic stenosis, heart failure (class NYHA III and IV), ACS within the previous 30 days, or QT interval prolongation. Before its use, the patients should be adequately hydrated. ECG and hemodynamic monitoring should be used, and the infusion can be followed by DC cardioversion if necessary. The drug is not contraindicated in patients with stable coronary artery disease, hypertensive heart disease, or mild heart failure. The clinical positioning of this drug has not yet been determined, but it is likely to be used for acute termination of recent-onset AF in patients with lone AF or AF associated with hypertension, coronary artery disease, or mild to moderate (NYHA class I-II) heart failure.",
"     <br>",
"      IV: intravenous; AF: atrial fibrillation; N/A: not applicable; QRS: QRS duration; QT: QT interval; T-U: abnormal repolarization (T-U) waves; DCC: direct current cardioversion; NYHA: New York Heart Association; ACS: acute coronary syndrome.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Sources:",
"     <br>",
"      <ol>",
"       <li>",
"        Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009; 2:652.",
"       </li>",
"       <li>",
"        Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008; 117:1518.",
"       </li>",
"       <li>",
"        Camm AJ, Capucci A, Hohnloser S, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent onset atrial fibrillation. J Am Coll Cardiol 2011; 18:313.",
"       </li>",
"      </ol>",
"      <br>",
"       Reproduced from: European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369, by permission of Oxford University Press. Copyright &copy; 2010.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19645=[""].join("\n");
var outline_f19_11_19645=null;
var title_f19_11_19646="Stool and diet history PI";
var content_f19_11_19646=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Stool and diet history",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 615px; background-image: url(data:image/gif;base64,R0lGODlhKwJnAsQAAP///wAAAIiIiLu7u0RERCIiIhERETMzM5mZmczMzO7u7lVVVd3d3WZmZnd3d6qqqsDAwBAQEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAArAmcCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY4sEQGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wkhA3AVq1UbePKLl1vLp8vjPBVMNLxb/Hb8m/vTjLT89G0YzTatXMys62UteJ3Wff2GvhJeTS3OLleObpZuwi70PxOvOA9V737V/x+T79Nf/2BMwyUB9BbS8WUHKQQuEDhCoGBGBQQEAJhZMYAjAQYIEIhQdY9FPAkcA6HgIo/y1QcMJBAIsnCEgq8LBHQS4YJWl0CbNESo3AILZwCCClyRNEabEQUIBBgAEXAzwsECDBRkkJEkgKuaJfSkkM7uT7WTQAUBcKTGot4K8PUaMryPbhByPpgadfA9DMGzJvTxfJHlg6S7QA26sGFizgyFVFv7t3GSoIYOBu08mV9YZFQLVj2ZkP7zrMSYCB4AOQWXLe+vklj7FmAQheoHWSxZQCMMs0YFXE6bZ87OJ1vbpjbUksBQplkTRpWZNvY1MN++KZAQQNjpLIGaABS45fUzZOkW/tWgCYASAIQCD9egJaQzYIgGAE3LuSagJQKECwSZkCxJccWdPtABtD8/Wklf8BZeVGWVkeAeBSacDt0ZxUuMUHwHwIyBWUUglJJcJdCTwgE2tEcSdidSpwVElyH4mYUgNXKWCYhl3xMB8lD6Qn4IPx5aWTiZOERKIITGU0m4QveaiifsvdIKRFDHCnAG7pLbkRgz/ctIVwCeAmpFkeKgeiC9GZxNEAGipU34w0LNNAARJBFdVDcHKUHI6O8cCRVUall9JKDw7K51VsBmBkVQAsWJYDS/IkIJLddYlSbCPwVyOWD2ophJdapNngoXDOFaUK3MH0FWSNMtYaoyyqUEADAnAZ1SQr1SjCobvsIJ4IJFVFWUkKYEasep01uZWiABy537KQesYTsqwJ2Vv/DgeSkABjenLK4JLpWRocJaoSl2xu+MGYB10H4TJEuMA+OM5JBol16hSgAvauvPHamka++NZr75lXACxSvQa7K3AzBFuRcJ8GPQzNwgzbIDEMF5+QcRsbG0MxHexi0TEJI1tD78dxhFwwOhGfjHI2tMQi88w012zzzTjnrPPOPPd8yr0sQ1Hyvy6/zDHQCguNcNFGz9twFUMDEDU4TDdN9NPEBN3O1EVwbTU9SCud9NZVf+1O2BOPnY7X8pjNhsoOa7122W6PATfUcovD9qd1m4x1wGrrTXffYNyddeDY7B2E4oRjjLYTUTNe+OCNd2E4EBLFEHkPAvz3F8l2wkDA/+cvjC516DZRbkLmemTeuakNrzcJjTuwHmsNDmhncUuzq7uU57ug7oLpM5j+1OqXi+AAV1pd6wPxfJvwAJcOUL+A7fAMgD0K0MPwOhNPua77ustxhnk37EgyfpzSGxBWAgdQ58Lr3YMuQ/2lW3R8CdsLo4KNFjnAWcgwjMlY5QC8aZYA+gcABpYAfy34XhPEB7vdkcB89nEfA67jlK0oQCJUSYxOilIAxnywFgzAD+0IsD6pSamFMgjG9FAHQspghCGyqxT9SAcP/NRnR/QBwOgIwJac8FBqPmxgZ+pjPKhg5AA2mgkCXHRE8qxgAAZwQAEUkEJJ0GiKkjhiXhIwRP/DWIQkJtJfErsoCeHFEAUHyE0WHZQAidwlgU/pTBE9OIIcIgCLlPnhJOrjEqzM7gRspBEbj2dE7nWGiJQJS/hq8TrOuHEOcMthpZYXRxI45QF1AkABTLIeEharIplbgCITyEKNvRBbJxDAHS0SylGqhxfruRLwNHabw4igASEhQPxIGBYISu02DLqObBjURFmyJI6sI8AAb5eC+ThxlWScprb2J8Rhms98xuvlfrjCTfbFcgEPQCc6GRRKAtBokkiCogJJQDwDWGSKMAKm1PQjQROoEgAbTMACyDmAWhXziK1cD1QqcjrxIWCY5IudL0dQAOadiD7RpCUlj+LOzCX/K4hWtEE/AaKCbYHyFqbL3EMnwYAdBg9ZRXERW4jXgBUe8XgS6SBLmwjE7rBuAHeBj+ZYwLqP/jGozuvjRIlHEqAyUX9QMV8B6nO6v23LAXJ0AENYV9OG3qKntBOB6ZxCnYnUaiYk7I4uU2DUqWavq0JEqEbFClXXcQRKA7OgUkuQO4bqczJ/ROlcX7fBwO4nrGJt4TtGak4SCMA7rdKeYBtYiwIwRDAtBV6t1HU8znxSQjNV1RYBuJ/xHU+LG6EqXU/nzBFIRF3/dNwVbxHbi9BoAbrTSuigJ0suNRGmimlUOf2HAgMkEIEP4eo7JcuS1ppAmiKwZ0y18hDUjuA6/7K87l9qux+P6JYpp0SmulI6WXjKUqF6yCQlaLVFrfyRI1QxbFwp2xqPZG6RxVSsxVj6NKDahr7zdd1MzAq8BXyuszOdSWiBdUeGGkB4k6CTEtH625wgQAGWOVEBknqw2YoAvxq2yoN9Mgky9mQyMPmt+RJAFapcUrZIoV4AWKLc02FYL8+ShGpviVGOKFPDW3QRFLfVnW2pC78s1stTbqwXixj4gXOdr3lJCdK8khQIjB0q4nZAEt/ZwEQmGK4S7gHmF2DRyyjQivwa6wWsukDNI7DRhQ2AZmo8jgZZhnHa3PHiI2xMgET979/MIJEwwkN9+kjelse8NCtXTgyKFv+bpMnm6EdPbtA0IMCOMY0Eye1DdSMQ83Or+AVj/iHSKWBjez5MZ/h5Ua97prQdiqGAnDCknPgzdRIcyILu8borfYb0nU2wPIAqsyhfZEjzrjzpuVV6RPIEalVXoGsk/FoF1f4QrGHAmTn3RsJxhhVxmy24Z2vFd4rS8XzHaDpgtnQmVkl3lSl7xwQ4JapsWaQT//uVDevR1Z45wQA60zkV0pcpJgR4hMK870LB25P4ud5T6NNvq/xbap3Z0XjAxulUH6ABifHNxqHL7Fg7e9YCnyg8xDk63Y5gdNlplVUc4BHXMIUE7WzAvYFLUIPGdVszl3g8VyDdxFKWAa4bbUX/suuYgjZlVwmk+Xa0IxGLAF1CCxflrS0yJwbs/DXDvohGoPtkBiN23CYvN8pNAGf7gVMAGBSrcTdDCbYgGOdf1fnd3Xo6uI5Ok3S6RZUUtekPT+TlVJoIBYWoc5AU/q1hBTwJ+A5gwCsAiMstylFEvW201yUkGHbAZJKDxcdrmdyJKxtqwiLtu7ecm9Ls+tVDjW+8//KdTCyid/Gi9AAlUASvdSxbNkuCos+XrBQsrH2GT2fQMYU6s78I1W8R/Vw2K/PfYyQM39hxFKj6SgsHa8kh1+i1m4ABJ8piVd/eGhNvaMN5yXzcAdzVVbElyS5mMkPjf+OKDHI/nwNILzFW/4pHSbjSGvVRdrQnRJLAIPEHcZIgdJTiRWw0K1WVfVAxYrDUfS1wAHi1gajHDJ6WOmHQduhBeSzQZTOQZ+jRfFRQZiA4fnizaLowgmDnBYXmGlKDaEXAghUjg4cTgsgAapa2MhwIPnmTes9WhFyAauRHg49ggwbChMJ2hB4DhY4ghRwXJ8FGheLSeUGYdkpofsLQhV5IgmAIOEJYg1UzPdsURXqRAED0bnEoNZxxdmeYhnoWN1jYCFoYg+GWAJ4lAFlnWVV1dVIXcHm4hUCohmIogqp3Xg1gYJd3SJ1Vd9O2iIDoeTO4hlFYNrVCI8YliDN2ffskc/ajiZvIfSKThP+QuIQuh1oVSCM7QoeVwnmqeHqN6IqM1jJLmIu8SE186IlZSITAeIV62IddU34/eIxhyGbD+IhD+IvO+ITJSIzn4ItkiBLbBwPXhmXdCGwwc43SmAR/2C7bGGpUVUomwII+aGYXM1LwJI5u4IRNsDna2IzqKALs6BPb944u8I0/kGXfiItnY4W9iI12toQgVUps5AA6hVh5YRKApEwDNwneF3F2RBlWcZFBVHFp0YATNm8k0EmZglWGoSgskUczkUjlkEQMRVZMQRXyFEuT4DlElEM0gnAqmWNQBEY6CI2c+Iz3yIwgswuV0F2RNVIu9zrShU/q50C45VrH406ptUz/iChxMKJMbtgSHmGVvPF8JFEf8/hPAUUyyCRKiddSl3FsJUBdmtdNa5ZL4AVArRVHJIeQroSO5fiJDLmOlUVVmjZSGNQ5ZAUPh+lAlKdcOqVjmOgS9tSYh9c+HeKBDngUbjWPRmU/ORWTBCYCKLhXcUk8KwUW3+NOYOVfQrWLwtiJfVmMf8mPtRBc37VxyzaV0rVZuXkLxldaVHl7Vwl1HKZmbilcwjN3teIR35OZzHVYL4VaVpkSmQWab+KCwmUVU0k8hohZhIVdNbkdtxWOvaKXnRaMfpmO8ACYAIUfysYRiKVxFOlj9SE7VNEqR6aReTeSwzc7OUgjHjl86zOV/4AVl6JElgPQf/hFMjMBFYV2F9NZoABYAjtiS8TTb2Z1gDlGHyG2EWa4l+Roja/ph8bIOWzhZkdwAB2aBCqIFHjojy8Ag7oolESJhPl4lEjwFRqYCCcCUSkAkKsYo64Joienj9WokBDTisq4COdInkUaPR9alEmqCEv6pL1Gak2qL0yajUYqpSOKbVbKUKN2pS6UpcsYpd7QpSmQbWJ6pKy5pU4qa0QqSg8nb0xkcKZTcZP3EjvHfmPkkab3aPZIo26KCFPapoZoc8y0eyaWlVC2p6HlctFVH115hoGKjCG6kOhZia+GUxNBPBoKd5hITwLgqHEVd5K5ZkxYqQl5qf9KWjXW93FVBZ0WgVkt93thGkRE9HPcVJx5qKrmaJ6wiZ6zuIN6ARUXZRF3ekii+hkHsGB9qkeL6KvlaaaESoS4ZqUm0JtrSjJht6pCqnZxynDL6gLzwaPbyq1kSgT4mGhoeq5o2Kas2jY1iknu+q2saISDegiFKqP1qqXwaq+WOqQ22q/eOpSOCLDTiJ4Eq67d+qvUqq/turDpOqZImq+GsK8GK7GL07DTarGFgLH3qrEMO7FvirBsSI0i+678Cqz+KrD0mrJlSqUBC6XsirIwy4hx4jM6u7M827M++7NAG7RCmwoc62csi6nherNTSLIb+7AXG7FK25ohG6Q0C6f/Axu1X/ivVWuy55m0WDuxkrOuVvuyX1shWiuo8XqmNlu2GSu1B7u14Hq1bIuzbeuxKhu3ZDu3dDu1MzqzY+i1egukfPu2aOuycgCyjSOtRuu0Hwu1gRtmRduycPu3cvu4ZxtSFZu21bq2ltthMluwhYu3h9u5kRtq28C4hIC4e0i6g7u6fQu6r6iwrIuln+uwdjsIquu2s9sCiiu5oUu5ebu7riu4hOu3sQu4wuuhlwu7zHuyspu8mLu8tqu5EMu50Gu6TAsEYmu4KXO9w/u9qHuDNfu83qsO2Zu1XBusyFu+FCu9HUu9T2u93tu7MQu/jSu/10u/I3u7gpC7tMu+/2y6suG7tOO7vuWrv/LKv4Hgv7wLwJ7rvourwPbguKyLwCU7ucdbuQ5svrX7vukrovgLvRbctBJ8ahRMuiOsvUfbqiGcvCmMvhicsAY8v6W7v/abuifcuS9sth+MtBq8wdjbwRF8w7ibw5a7w3f7uxkcvECMrkLsu8Yrwz/cxEgsvkTcv0b8uFVMwFe8wFkcuFu8t1HsvDOcvzWcwF08wS0svGH8o83btVMMxG18xmIsxUzcxPBAxyScxia8xrs7x+f7xDjsx7MLyIJsxdwLBwxsNoYMwTwsut2Lx5AbyEk8xnB8x3jcyALswZCsyJI8yYeMxj3MwuTrwJpct0OcyP/j+Ml5TMmIHMNkHMcbfMqtO72qXI+s7MSOXL+jzKWEXMF6rMID7MW/jMLBDMNKbMejm8utHMoXnMyxjMlUfMyPDM2XvMzMTMvE+8bqK8umTM2VzM0gXMoArM3gy8nAi825bM66a8udvMqszM7/28tqS87sK88NPMxqbM8HDM6vbM3dLM1y7M9cTM+by8807MoFDcvXHMnZTNB17M7p7NDrDNFuLNFLrM7xbNEc3c4N7cnM3L6bzMcKHVEIbcYlfdHonNEUvdEp3dHz/M64HNL4/MAGXb0nLcIwvcv/zNIg/dAvHdQxPdE/XdFCzdMLTdTw/Mn8MLRO/dRQHdVSPdX/VB20Oz3SUKzMLc3UV43KWR3NGs3VR43VvCzTR0PTXV3LK63VRe3SzrzHNx2/Oe3Cab3NGM3WSy3JNZ0j+tzHc83GdX3OqWzWbxPSIu3VDD3YSj3TQP3WwlzCfrDIfN3YSP3MlhzQYa3Xge3Riu3TeZ3Jmz3Ulz3OZazTY43YNnzLZ03ZZA3QX/3Rnz3Np63WnY3XjG3Ujo3Mo+3DAj3LoZ3PkF1BpU3Xs23Xaw3WW63ZxS3Yr43ZyQ3ay83ZzU3a3lzOv23TiU3dvf3N0S3a4szbmQ3duV3Nu03Kww3Y3Q3cJC3c1X3P1z3Z661t5/3H7x3A2Q3ezy3b4x3Od43c/20t1vvd099t3u3dz+mN3a6N3/+t3AGe1OXty39N3wcO33F9vxFeyPUdvRU+yBcOzBNu3wlO4Ntt3R+u4fct4uGt35UN1ycO4fON4SU+nsEt3wWe0A0e0ccN27ft1iv+2PFtJh1uzDGuvBtexMWswxku4z+eXl+st3sN4g9ezy/u4Teu0rXt37E90EMOyktu0lMu5FWe4ZId5VSD1lvOwV3e5Fsw5k3z5CYe4i5e4ygd5iXO5v294wDe47o94HE+4u595rpc5Fh85Eec5ETe4lIu56ZN54yu3qpd2Gbe6K0tyoTtNKyN2mTu449u6bit5+TN54nu5wYu6Zhu2ba92v+dPumgzuKLjeo8rup3fuU67up5Dus5LuvOveDi7en8fevaneJaTuq0Pd0KnuW+DehBnOaEjg+G7eZKLujEHORIjuzNrOzS/mmRzusCHuu/nt/Bru0Ovuo4/eXTLuzGjevdrusqbuvoXtatDumXPuyIzuqejecMDu443u4o7u3Hbu7M7e71Tuv3zu7EntqV7jfxfu7QbuXpbuzc7e/SDfCnDu+pXurcLvFYbu+7TvAY7+vFrvHrbvEeb/DvzumvLvL6Tuklj/AVL+9wbuoZL/Abj/IFr/IBT/EnH0NVvfM83/M+//NAL9WGzuUL79fkXujUftgvf9BHr8VDj+ZFH9n/as62zn7oSz/uik7cEO/dF7/v6v7tHE/ymS7XTQ/GTx/o8471om7j+M7wHZ/rDk/iW+/oaU/2WY/ec4/gY2/hZe/kZ5/sUc/eaz/nbS/mRjn4i174dX74wN7vip/3gH/wV5Pw/371ex7zOF/rNP/2NR/qjf/wjx/6ej/xJq/5Lr/3vQ73IA/2my/24m73iK/1ot/64Y75pT/wtA/zI9/nny/3s3/6uq/6Mh/ywN/1Nk/6LJ/zCl/3n277yW/6y2/5zT/rmY/7xb/7wd/wq+/4YX/8xu/5/A763Z/9nP/xw8/615/y5O/1cf/nkA/lr8/3dy/h7//mqG/k1+70Sb+9/5IPAoA4kqV5oqm6mgH7wrE807V947eb77mf9n64oLBoPJ6IyOWQ6XxCo1KAkladvq7YkXbrXXa/0bC4bD7XyCy1mT1Gw4XuuG9Ov+Ox9mS+tGf+9cEFCmYVHiJKEXIhLho5JupFPk5WWjbxNNJBXjpxWn52it5BhoJtjvaZRq6mun6Vasa1vurUztDe6gLWyQ7uouUWCgMX92YeEssoGwM1qzA/SxsiD6NOS2L7aXN7xSZfdz9Fk4qbQ31bz557npOzT6cLvq/Qx7vD5xfJq4bry+H7J9AGvzz2nA38cfDMwoSuCuJp2MLhMXESKXaCWG4dRlvmLnaspNEfw5AEA/+aTEml4jySKtegfNlxJMdfMmGA9HYzJE2bPndCiwl0YM9gLodu+4jUYdGSNZdOVApVYNM2R6fm3JJ1qtVqLZ9yFbF1ytiwOr32Axu27Buz8KqW2co21dxxbt+yTPvTbN12d4Wm8WX0b19ef6ViUrd3LeDD99AavAq18CnH3eCKkXuYMhLOlgFCjih5qWdKn7VhhjUaael9p1HnjayWa2vQr6WlPruYduPbu3JrXT20tkLfuGOLno21t/FawLPtXo64ObDnZIUDJY6c+ivrirDv1B6a+8Pt4NveFZ+Y/C3v6AenZ84+o3nlqgnLnw+qfvT78afrRxd/8BHIV34BsjL/oFP9kXYggoIRFICEE1JYoYUXYpihhhty2KGHH4IYoogjkliiiSeimKKKK7LYoosvwiihgl0xyJqDDyrmUY4LuqWejjjSN9556Gx2I5CyradXgYwBeOQk7hFpX4NNOpkIlHZJaSOVVYIjZJbQ9WgklzVSsyONYW45ppIndUlmdmKqeSabZsZVZJpxbpQkkkvydieeX8LUJp/SWfQnhIEJyqOBfhqqKKJ0ZmZnoY1+pWdyboYHJ6XXeYnpe4tOuumlP64pJ5OhijokCpRphh+jqQbX6aD+oYkqrLPGwKqqKvk456244nRona7a+uuwluYJ7HCaGtvZjMcq++arzWKJ/+yuhv1XLLWxWgvod8Retq2pVggbKbjc9PrglX55KlO65IprbrftVltruPHS6mup0IJ6L77ckrqno31q+2+9+go8LqH+GvztvNE6bC+6DYOJ8KgDLzwxxRFbnCzGkzG7MbwPf6ybxLCJHCXJCud7KsMpV7YyvyxPWTDMtgV8Mc1a2nzzswhB2jLBL/vsmqwlA9yvxkUfsS62EN/0Li5MO3v0zhW7vDTVOHd8bcwnYyO1fk5/jfSy024drNUzs50xymkXt7a8ULsbMtxRyTy32dL2fHeuPwutd9Zv+53z1IlezTfRhR+ed+CP17w443/LDXnSg4c9ueHLlGv52X1rDv/05t5+ivljoTc+Or3sgn066pQ7bvLemaL9uliAy5447aDbTgLZVa+ektiw9x5o7Je3DXLttv/etNc82T1586YFb9LwahdvvOp0H2z6cdlr3zXpKrf+PfhBVZ578pFrfT4f6SMv+NDtu5/U8Vivz7Pk9a8EP/7yuy1z/Hvf/ThVPegt73XTM9oBZxI9xi2Qa7qL2gMLF8G4NRAj1yvTAH2Hu/h5TnH06+AFP1g27z1jg9wpof+AV74UdhBv25td6eZHuBj2r4Acm2DdEog6FuqQei9shgqpA8QZ7tCGAsTh7VqYRAAqj3fZO6L4QMi+G8awFDHaIhe76MUvgjGMYhz/IxnLaMYTmdCA3ONVBf1GxUetUXhtvNsbRxZH680RbnVMHQ17KMXi7ZFz43tJEdHHxBwiMX//i+L+6hdI4vWRkHlM2yOxd0cE/rF3leRgJNnow9BtMnw8lOQnNRfKejzPgaWUXhqfGMLdNdJ9pzTkJVWZSea1soZQvOISmThL0XVSjquEYC7JF0w8DtOCxeyeIkWIRRIuk3XHxGQsz/fLVaVSg5Pc2jUJWEttJtON0XzaNG1ZTfB1U4blBOctFTjOEzYTliMcYDrt902KFBKYWXynC9eJz21SrZ4eHKQn2/lDfjqPoMI0KCgRKkR/MgWgTBMoIxSKTIaa0qEMvGdE/8NJR41KMJ4U9KgeQYpBjiYkn9g8JCKriFKTkvRJLG0pHPe1S/3Nk38UbWIG/xlTbsLUiQ9FIRFnulOaitSP55xiUIO4UaU9k55NTaQxiWoMld7mqK3K1lIBOVWXqhGqvcShVrPpU4yyUqhVTSop0UpMtTLzpp/rqia/WtNRFpSuuISrNPG6UL26k6/k9OtFAXtQwcJTrs4c6z4R20/CUjOnjrSrHSGaUokWrawWjWxUdUpZPkLWnJKV5WcF2dOOulWZjk3oaS/704CWFpKhZadhG7raobI1r6O1ZmwtaVmiYNZnmm0tcF870d5ycrZnrW1Gb/tU5aKWuWl1alxfOf/S1IrTuSFVrDw7O1ntnvS3VAnuzYb70vEaN7PIFWVu/7pbdK4XlZsVrXdJC9748nSIVzUqfvXZ3sK+l6n3HbBvrVoMrL7GvOL9B4LtSdb+rpS46MXuRwlM1ery0nUPtjBYXZlh8/kSwt5csD4aPNBDKhi6rqVwSTl81/9ylrHQdHFlVVxcFlNSxOq08YSl+1bq9hXG9JWxVGkMWiHTNsBe5cEZm+zkJ0M5ylKeMpWrnCIdO5jHDCYvzFKM5OUqua5GNu15t5xe4WL5xGUuMZdT5mXuXtfHqgXyYL8c3TDvlc6Jta5S8RxYPT/WziuWc3YBzdo158PEFUVxmheNaLz/nLm8jc4viRPdZpG9mc9tJXSFDY1bOPe5vrwds2wFfWNOt9jTzzV1j/18WFVvV9O6FTV8SV1gVpsZx0C1dXJxzeZId3nSSAX1pl1tW1iHV8u/1jVsec1eYs+ayJ51tnwlnGtU55jatKw0pJl9XG37F9rupbWAkd1fRa9Vw401N7jRjeGisjTT6gugumfM7nv3mt4g3jC+O6xLRhq7uf1+sbgBTO4lD7zGvrY0sN0s7K3q98D8BXeEH80Od7v7XAQ3a6w/DMN4P5zjgw74dC88b1mPW9rfTfiRCx7jeheZ5WTm9sUvvTF5WxGnBxezzEvt8iHDfNo9v/XPk7zzPJs8/+eL9Di8GU3xESub4d5W79N3vPBuY3vXQ883yg2ucvtu/dldf/m+1530pSt9sUFf+dnDGnWsk/zHbfdw2rv79VGHvdoWt7nIUz33f5+c6fsFedWzfPWaNxzTIZ+v0e9e67xv++2InzqaC69mmvOd8XP+e7rHDvSy25vz70b7XOO+eX8XfdX6/rjTIR9uzzd+7WAXfZBTf+ej/5n2dbb9yHH/at3vOfA6d3y5gR9o3p/a9IU2/qExn3iPmR31sFc9wH1/bOZ/evq3Jz7CsU994Zfe+gL3fsfrHmfld5r8yT585q3dbNdX3PmUr1SILe9o+WfdShOHP9TZ//y+Zxv/WaMd8rWa+JWc9IGf2ymR7OGd+p2bpOTftwmg4RHgtaGf3yGg+XWe4Ekc4U3g5Ule++1dsNkfpYXg/2ne8mUg6Sng6jVd/X3g/Z3g/NmU0Dlgu0HgBQbgDbpexu0e6MUcDwqh2HFgdeyfDlhZEirhEjJhEzrhE1IZBMzUFFJhFVrhFWJhFmrhFnJhF3rhF4JhGIrhGJJhGZrhGaJhGqrhGrIhnoQAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19646=[""].join("\n");
var outline_f19_11_19646=null;
var title_f19_11_19647="Folate synthesis";
var content_f19_11_19647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71984&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mechanism of action of antifolates",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 525px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_11_19647=[""].join("\n");
var outline_f19_11_19647=null;
